# 2025年12月10日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 个体化新抗原治疗发展的最新进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364340)
**期刊：** The Journal of experimental medicine
**PMID：** 41364340
**DOI：** 10.1084/jem.20241234

### 第一部分 原文与翻译

**英文原标题：** Advances in the development of personalized neoantigen therapies.

> **英文摘要：**
> The ability to specifically engage tumor-reactive T cells for therapeutic benefit is the ultimate goal of cancer immunotherapy. Whereas currently approved immunotherapies leverage and modulate existing endogenous T cells in an antigen non-specific manner, cancer vaccines and neoantigen therapeutics promise the ability to selectively amplify T cells specific for targeted antigens. Advances in the identification of tumor-specific antigens coupled with a greater understanding of T cell biology and immunization platforms have culminated in recent trials where signs of clinical efficacy have been observed, particularly in randomized adjuvant clinical settings. In this review, we discuss the identification of tumor-specific antigens for cancer therapy, the benefits of including antigens recognized by CD4+ T cells, clinical data investigating novel immunization platforms, and emerging clinical settings where promotion of tumor-specific immunity may be optimal.

> **中文摘要：**
> 能够特异性激活肿瘤反应性T细胞以获得治疗收益，是癌症免疫治疗的终极目标。目前获批的免疫治疗主要通过抗原非特异性方式利用并调控体内已有的T细胞，而癌症疫苗与新抗原治疗则有望选择性扩增针对特定抗原的T细胞。肿瘤特异性抗原识别技术的进步，结合对T细胞生物学和免疫接种平台的深入理解，促成了近期临床试验中观察到的疗效信号，尤其是在随机化辅助治疗环境中。在本综述中，我们讨论了用于癌症治疗的肿瘤特异性抗原的识别方法、包含CD4+ T细胞识别抗原的潜在益处、探索新型免疫接种平台的临床数据，以及促进肿瘤特异性免疫可能最为理想的新兴临床场景。

### 第二部分 AI 大师评价

本文综述了个体化新抗原治疗的研究进展，重点关注肿瘤特异性抗原的识别、CD4+ T细胞相关抗原的价值以及新型免疫接种平台的临床前景。作者指出，新抗原疗法能弥补现有免疫治疗的非特异性局限，展现出强化特异性抗肿瘤T细胞应答的潜力。该研究突出了随机化辅助治疗环境中出现的初步疗效信号。但目前仍面临个体差异、抗原预测准确性和免疫持久性等挑战，需在未来试验中继续优化。

---

## 2. 力学代谢调控造血干细胞的特化过程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364073)
**期刊：** The Journal of experimental medicine
**PMID：** 41364073
**DOI：** 10.1084/jem.20250607

### 第一部分 原文与翻译

**英文原标题：** Mechanometabolism instructs hematopoietic stem cell specification.

> **英文摘要：**
> Mechanical force generated by blood flow stimulates emergence of the first hematopoietic stem cells (HSCs) that populate the blood system. Force drives the transition of HSC precursors from an endothelial to hematopoietic identity, yet the molecular regulation of this fate switch remains poorly understood. We report that shear stress triggers adaptation in mitochondrial composition, ultrastructure, and function, which are essential for hematopoietic fate and engraftment potential. Shear stress remodels mitochondria in hemogenic endothelium by promoting mitochondrial gene transcription and protein synthesis. Laminar flow selectively initiates translation of 5' terminal polypyrimidine (5'TOP) motif-containing transcripts, which commonly encode ribosome and translation machinery. Flow-responsive metabolic reprogramming depends upon mechanistic target of rapamycin (mTOR) activation and is stymied when ribosome activity or mTOR is blocked. Conversely, chemical induction of mTOR mimics the effects of force on mitochondria and blood reconstituting potential and also partially rescues hematopoiesis in heartbeat mutants in utero. These findings identify mechanometabolism as a determinant of hematopoietic fate that could inform engineering of HSCs for disease modeling and treatment.

> **中文摘要：**
> 由血流产生的机械力可刺激最初造血干细胞（HSCs）的出现，这些细胞是血液系统的起源。机械力驱动HSC前体细胞从内皮表型向造血表型转变，但这一命运转换的分子调控机制仍不清楚。我们报告称，剪切应力会触发线粒体在组成、超微结构和功能上的适应性改变，这些改变对造血命运的确定与移植潜能至关重要。剪切应力通过促进线粒体基因转录和蛋白合成来重塑造血内皮中的线粒体。层流选择性地启动含有5'端多嘧啶（5'TOP）基序的转录本的翻译，这类转录本通常编码核糖体及翻译装置。与流动相关的代谢重编程依赖于哺乳动物雷帕霉素靶蛋白（mTOR）的激活，当核糖体功能或mTOR被抑制时，该过程即受到阻碍。相反，化学诱导mTOR的激活可模拟机械力对线粒体及血液重建能力的效应，并可部分挽救子宫内心跳突变体的造血功能。这些发现表明，力学代谢是决定造血命运的重要因素，可为造血干细胞的工程化及疾病模型与治疗研究提供启示。

### 第二部分 AI 大师评价

本文揭示血流引发的机械力可通过调控线粒体代谢和mTOR信号通路影响造血干细胞的命运决定，提出了“力学代谢（mechanometabolism）”这一新的概念。研究通过细胞层面的功能和分子机制实验，明确剪切应力对线粒体基因表达、蛋白合成及5'TOP转录本翻译的促进作用。其创新在于将力学信号与代谢重编程及造血干细胞特化建立联系，为人工诱导HSC生成提供了潜在策略。但仍需进一步验证该机制在体内不同发育阶段和物种中的普遍性。

---

## 3. 基于外泌体的液体活检用于早发型结直肠癌检测：ENCODER多中心研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364052)
**期刊：** Gastroenterology
**PMID：** 41364052
**DOI：** 10.1053/j.gastro.2025.08.013

### 第一部分 原文与翻译

**英文原标题：** An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study.

> **英文摘要：**
> BACKGROUND & AIMS: The incidence of early-onset colorectal cancer (EOCRC; diagnosed before age 50 years) continues to increase, now standing as the leading cause of cancer-related deaths in young men. Screening participation in young adults remains low, but a noninvasive test may help.
> 
> METHODS: Early Onset Colorectal Cancer Detection (ENCODER) was an international, multicentric cohort study involving 542 individuals from 4 countries (ie, United States, Italy, Spain, and Japan). A panel of 6 cell-free and exosome-based circulating biomarkers were identified through small RNA sequencing from a biomarker discovery cohort (n = 118). A machine learning model (Extreme Gradient Boosting) was then trained on reverse-transcription quantitative polymerase chain reaction results from a training cohort (n = 192) and tested in an external and independent cohort (n = 191). Finally, we investigated the temporal dynamics of biomarker levels before and after surgery (n = 41).
> 
> RESULTS: Our liquid biopsy was highly accurate in detecting EOCRC in 2 independent cohorts (area under the receiver-operating characteristic curve, 97.5% in training vs 95.6% in testing). In the independent testing cohort, patients with EOCRC could be readily distinguished from nondisease controls, even in the age range from 20 to 35 years (area under the receiver-operating characteristic curve, 98.5%). This liquid biopsy had a specificity of 87.5% (95% CI, 79.4%-92.7%) and an overall sensitivity of 91.6% (95% CI, 84.2%-95.7%); the sensitivity for screening-relevant EOCRC stages I-III was 97.3% (95% CI, 90.6%-99.3%) and the sensitivity for premalignant lesions with high-grade dysplasia was 61.5% (95% CI, 35.5%-82.3%). Finally, we observed a reduction in the liquid biopsy values after surgery, reaching negativity after 4 days.
> 
> CONCLUSIONS: ENCODER represents the largest EOCRC study to date to develop, train, and externally test a liquid biopsy for the growing population at risk of EOCRC, offering a complementary screening strategy.
> 
> CLINICALTRIALS: gov, Number: NCT06342401.

> **中文摘要：**
> 背景与目的：早发型结直肠癌（EOCRC，指50岁前确诊）发病率持续上升，现已成为年轻男性癌症相关死亡的主要原因。年轻成人的筛查参与率仍然偏低，但一种无创检测方法可能有所助益。
> 
> 方法：早发型结直肠癌检测（ENCODER）是一项国际多中心队列研究，涵盖来自美国、意大利、西班牙和日本共542名受试者。通过小RNA测序，在生物标志物发现队列（n = 118）中筛选出6种基于细胞游离与外泌体的循环生物标志物组合。随后基于反转录定量聚合酶链反应结果，利用极端梯度提升（Extreme Gradient Boosting）机器学习模型在训练队列（n = 192）上进行训练，并在外部独立队列（n = 191）中验证。最后，我们研究了术前、术后生物标志物水平的时间动态变化（n = 41）。
> 
> 结果：该液体活检在两项独立队列中检测EOCRC的准确性极高（受试者工作特征曲线下面积：训练集97.5%，测试集95.6%）。在独立测试队列中，即使在20至35岁人群中，EOCRC患者也能与健康对照明显区分（AUC为98.5%）。该液体活检的特异性为87.5%（95% CI, 79.4%-92.7%），总体敏感性为91.6%（95% CI, 84.2%-95.7%）；针对与筛查相关的EOCRC I–III期，其敏感性为97.3%（95% CI, 90.6%-99.3%）；而对高级别上皮内瘤变等癌前病变的敏感性为61.5%（95% CI, 35.5%-82.3%）。此外，我们观察到术后液体活检数值下降，并在4天内转为阴性。
> 
> 结论：ENCODER是迄今规模最大的EOCRC研究，开发、训练并在外部验证了一种液体活检方法，为不断增长的EOCRC高风险人群提供了一种互补的筛查策略。
> 
> 临床试验注册号：NCT06342401。

### 第二部分 AI 大师评价

本研究旨在开发并验证一种基于外泌体的液体活检方法，用于早发型结直肠癌的无创检测。研究通过多国多中心大样本队列设计，利用机器学习对小RNA来源的循环生物标志物进行筛选和模型训练，并在独立队列中验证其性能。结果表明该检测具有极高的准确性与敏感性，尤其对早期病变检测表现优异。其创新性在于将外泌体标志物与人工智能模型结合，实现精准风险识别。然而，仍需进一步研究评估其在临床筛查流程中的可行性及成本效益。

---

## 4. Teclistamab联合Daratumumab用于复发或难治性多发性骨髓瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41363801)
**期刊：** The New England journal of medicine
**PMID：** 41363801
**DOI：** 10.1056/NEJMoa2514663

### 第一部分 原文与翻译

**英文原标题：** Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

> **英文摘要：**
> BACKGROUND: In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma.
> 
> METHODS: In this phase 3 trial, we randomly assigned patients with one to three previous lines of therapy to receive combination therapy with teclistamab-daratumumab or daratumumab combined with dexamethasone plus the investigator's choice of pomalidomide (DPd) or bortezomib (DVd) - the DPd or DVd group. The primary end point was progression-free survival, as assessed by an independent review committee.
> 
> RESULTS: A total of 587 patients underwent randomization (291 to receive teclistamab-daratumumab and 296 to receive DPd or DVd). At a median of 34.5 months, progression-free survival was significantly longer with teclistamab-daratumumab than with DPd or DVd. The estimated 36-month progression-free survival was 83.4% in the teclistamab-daratumumab group and 29.7% in the DPd or DVd group (hazard ratio, 0.17; 95% confidence interval, 0.12 to 0.23; P<0.001). More patients in the teclistamab-daratumumab group than in the DPd or DVd group had a complete response or better (81.8% vs. 32.1%), an overall response (89.0% vs. 75.3%), and minimal residual disease negativity (10; 58.4% vs. 17.1%) (P<0.001 for all comparisons). Serious adverse events occurred in 70.7% of the patients in the teclistamab-daratumumab group and in 62.4% of those in the DPd or DVd group; death from adverse events occurred in 7.1% and 5.9%, respectively.
> 
> CONCLUSIONS: In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).

> **中文摘要：**
> 背景：在一项 1–2 期试验中，Teclistamab（一种靶向 T 细胞表面 CD3 及骨髓瘤细胞上 B 细胞成熟抗原的双特异性抗体）在经多线治疗的复发或难治性多发性骨髓瘤患者中显示出持久疗效。Daratumumab（一种靶向 CD38 蛋白的单克隆抗体）已被证实能改善多发性骨髓瘤患者的生存。
> 
> 方法：在本项 3 期试验中，我们将既往接受过一至三线治疗的患者随机分配至 Teclistamab-Daratumumab 组合治疗组，或 Daratumumab 联合地塞米松并加研究者选择的来那度胺或硼替佐米的治疗组（分别记为 DPd 或 DVd 组）。主要终点为独立评估委员会确定的无进展生存期。
> 
> 结果：共 587 名患者被随机分配（291 例接受 Teclistamab-Daratumumab，296 例接受 DPd 或 DVd）。在中位随访 34.5 个月时，Teclistamab-Daratumumab 组的无进展生存期显著长于 DPd 或 DVd 组。估算的 36 个月无进展生存率分别为 83.4%（Teclistamab-Daratumumab 组）与 29.7%（DPd 或 DVd 组）（风险比 0.17；95% 置信区间 0.12–0.23；P<0.001）。Teclistamab-Daratumumab 组完全缓解或更佳缓解的患者比例（81.8% 对 32.1%）、总体缓解率（89.0% 对 75.3%）及微小残留病灶阴性率（58.4% 对 17.1%）均显著高于 DPd 或 DVd 组（所有比较 P<0.001）。严重不良事件发生率分别为 70.7%（Teclistamab-Daratumumab 组）与 62.4%（DPd 或 DVd 组）；因不良事件死亡的比例分别为 7.1% 与 5.9%。
> 
> 结论：在既往接受过一至三线治疗的多发性骨髓瘤患者中，Teclistamab-Daratumumab 联合治疗显著延长了无进展生存期，相较于 DPd 或 DVd 治疗方案。（由强生公司资助；ClinicalTrials.gov 注册号 NCT05083169。）

### 第二部分 AI 大师评价

本研究是一项随机、对照的Ⅲ期临床试验，旨在比较Teclistamab与Daratumumab联合治疗与标准三联方案（DPd或DVd）在复发或难治性多发性骨髓瘤患者中的疗效与安全性。结果显示，联合方案显著延长了无进展生存期并提高了完全缓解和微小残留病阴性率。尽管严重不良事件较高，但安全性总体可控。该研究为双特异性抗体与CD38单抗联合治疗提供了强有力的临床证据，具有潜在的临床实践转化价值。

---

## 5. 伊那鲁单抗联合艾曲波帕治疗免疫性血小板减少症

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41363800)
**期刊：** The New England journal of medicine
**PMID：** 41363800
**DOI：** 10.1056/NEJMoa2515168

### 第一部分 原文与翻译

**英文原标题：** Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

> **英文摘要：**
> BACKGROUND: Current second-line treatments for immune thrombocytopenia (ITP) require long-term administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line therapy in ITP.
> 
> METHODS: In this phase 3, randomized, double-blind trial, we assigned, in a 1:1:1 ratio, adults with primary ITP and an insufficient response or a relapse after first-line glucocorticoid therapy to receive ianalumab at a dose of 9 mg or 3 mg per kilogram of body weight or placebo once monthly for 4 months. Eltrombopag, an oral thrombopoietin-receptor agonist, was administered once daily in each group according to local prescribing information; the dose was tapered until discontinuation by the end of week 24 in eligible patients. The primary end point was freedom from treatment failure, as determined in a time-to-event analysis, with treatment failure defined by a platelet count of less than 30×10 per liter more than 8 weeks after randomization, initiation of rescue therapy more than 8 weeks after randomization, initiation of new ITP therapy, inability to taper or discontinue eltrombopag because of an inadequate platelet count, or death from any cause, whichever occurred first. The key secondary end point was a stable response at 6 months, defined by a platelet count of at least 50×10 per liter in at least 75% of the measurements between weeks 19 and 25 without use of rescue therapy or new ITP therapy. Safety was assessed.
> 
> RESULTS: A total of 152 patients underwent randomization: 50 to the 9-mg ianalumab group, 51 to the 3-mg ianalumab group, and 51 to the placebo group. The estimated probability of being free from treatment failure at 12 months was 54% (95% confidence interval [CI], 39 to 67) in the 9-mg group, 51% (95% CI, 36 to 64) in the 3-mg group, and 30% (95% CI, 18 to 43) in the placebo group. The time to treatment failure was significantly longer with ianalumab plus eltrombopag than with placebo plus eltrombopag; the estimated hazard ratio for treatment failure (ianalumab vs. placebo) was 0.55 (P = 0.04) in the 9-mg group and 0.58 (P = 0.045) in the 3-mg group. The percentage of patients with a stable response at 6 months was significantly higher in the 9-mg group than in the placebo group (62% vs. 39%; P = 0.045). The overall frequency of adverse events during the treatment period was generally similar in the three groups. The frequency of serious adverse events was 16% in the 9-mg group, 6% in the 3-mg group, and 4% in the placebo group.
> 
> CONCLUSIONS: Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag. (Funded by Novartis; VAYHIT2 ClinicalTrials.gov number, NCT05653219.).

> **中文摘要：**
> 背景：当前免疫性血小板减少症（ITP）的二线治疗需要长期用药。伊那鲁单抗是一种靶向B细胞的单克隆抗体，正在评估其作为ITP的短程二线治疗方案的疗效。
> 
> 方法：这是一项III期、随机、双盲试验。研究将对一线糖皮质激素治疗反应不足或复发的成人原发性ITP患者按1:1:1比例分为三组，分别接受每月一次、连续4个月的伊那鲁单抗9 mg/kg、3 mg/kg或安慰剂治疗。艾曲波帕（一种口服促血小板生成素受体激动剂）在各组每日给药，按照当地用药指南调整剂量，在符合条件的患者中于第24周前逐步减停。主要终点为无治疗失败状态（基于时间事件分析确定），治疗失败被定义为随机化8周后血小板计数低于30×10^9/L，或随机化8周后开始救援治疗、启动新的ITP治疗、因血小板计数不足而无法减停艾曲波帕，或任何原因导致的死亡，以先发生者为准。关键次要终点为6个月时的稳定反应，定义为在第19至25周期间，至少75%的测定值血小板计数≥50×10^9/L且未使用救援或新ITP治疗。研究同时评估安全性。
> 
> 结果：共152例患者入组随机分配，其中9 mg组50例，3 mg组51例，安慰剂组51例。在12个月时无治疗失败的估计概率为：9 mg组54%（95%置信区间[CI]，39–67），3 mg组51%（95% CI，36–64），安慰剂组30%（95% CI，18–43）。与安慰剂联合艾曲波帕相比，伊那鲁单抗联合艾曲波帕显著延长了治疗失败时间；伊那鲁单抗与安慰剂比较的治疗失败风险比为：9 mg组0.55（P=0.04），3 mg组0.58（P=0.045）。6个月时达到稳定反应的患者比例在9 mg组显著高于安慰剂组（62%比39%；P=0.045）。治疗期间三组总体不良事件发生率大致相似，严重不良事件发生率分别为9 mg组16%、3 mg组6%、安慰剂组4%。
> 
> 结论：伊那鲁单抗联合艾曲波帕相比安慰剂联合艾曲波帕，可显著延长治疗失败时间。（由诺华公司资助；VAYHIT2临床试验登记号：NCT05653219。）

### 第二部分 AI 大师评价

本研究是一项III期随机双盲对照试验，评估伊那鲁单抗联合艾曲波帕在原发性免疫性血小板减少症中的疗效与安全性。结果显示，联合治疗能显著延长治疗失败时间，并提高6个月时的稳定反应率，提示短程B细胞靶向治疗可增强促血小板生成疗法的持续效益。安全性总体可接受，严重不良事件率略高。该研究为ITP二线治疗策略提供了有潜力的新思路，但仍需进一步验证长期疗效与免疫学机制。

---

## 6. BRUIN CLL-313：皮托布替尼与苯达莫司汀联合利妥昔单抗在未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中的随机III期试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41363773)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41363773
**DOI：** 10.1200/JCO-25-02380

### 第一部分 原文与翻译

**英文原标题：** BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

> **英文摘要：**
> PURPOSE: BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
> 
> METHODS: Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)-assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)-assessed PFS, safety, and tolerability.
> 
> RESULTS: Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367];  < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)-related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively.
> 
> CONCLUSION: Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.

> **中文摘要：**
> 研究目的：BRUIN CLL-313是一项随机、开放标签、全球性的III期研究，旨在比较高选择性、非共价布鲁顿酪氨酸激酶抑制剂（BTKi）皮托布替尼与常用一线化免疫治疗方案——苯达莫司汀联合利妥昔单抗（BendaR）在未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者中的疗效与安全性。
> 
> 研究方法：入选患者须为未经治疗且无del(17p)的CLL/SLL患者，按1:1比例随机分配接受持续皮托布替尼单药治疗或BendaR治疗，并按免疫球蛋白重链基因突变状态及Rai分期进行分层。主要终点为独立评审委员会（IRC）评估的无进展生存期（PFS）；次要终点包括总生存期（OS）、研究者（INV）评估的PFS、安全性及耐受性。
> 
> 研究结果：共282例患者被随机分配至皮托布替尼组（n=141）或BendaR组（n=141）。IRC评估的PFS显示，皮托布替尼较BendaR显著改善（风险比[HR] = 0.199；95%置信区间[CI]：0.107–0.367；p < 0.0001），24个月PFS率分别为93.4%（95% CI：87.6–96.5）与70.7%（95% CI：61.5–78.1）。研究者评估的PFS结果同样支持皮托布替尼的优势（HR = 0.186；95% CI：0.093–0.371）。在中期分析中，尽管存在52.9%的有效交叉率，皮托布替尼仍表现出OS获益趋势（中位随访32个月；HR = 0.257；95% CI：0.070–0.934）。不良事件（AE）相关剂量降低分别发生于3.6%与31.1%的患者中；≥3级治疗相关不良事件（TEAE）发生率为40.0%与67.4%；因TEAE停药的比例分别为4.3%与15.2%。
> 
> 结论：在未经治疗的CLL/SLL患者中，皮托布替尼在IRC评估的PFS方面优于BendaR。尽管研究允许交叉治疗，OS趋势仍倾向于皮托布替尼。皮托布替尼耐受性良好，安全性符合其既往已知特征，且优于BendaR。

### 第二部分 AI 大师评价

该研究通过全球随机III期临床试验系统比较了皮托布替尼与BendaR在初治CLL/SLL患者中的疗效与安全性。结果显示，皮托布替尼在无进展生存期方面显著优于BendaR，并且具有更低的高等级不良事件发生率和更好的耐受性。尽管研究允许交叉，皮托布替尼在总生存期上依然呈现优势趋势。该研究验证了非共价BTK抑制剂在一线治疗中的潜力，但长期随访和不同生物亚型的疗效差异仍需进一步研究。

---

## 7. BRUIN 313 与 314 试验为非共价布鲁顿酪氨酸激酶抑制剂作为慢性淋巴细胞白血病一线治疗开启新局面。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41363770)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41363770
**DOI：** 10.1200/JCO-25-02691

### 第一部分 原文与翻译

**英文原标题：** BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究报道了BRUIN 313与314两项试验，探讨非共价布鲁顿酪氨酸激酶抑制剂作为慢性淋巴细胞白血病（CLL）初始治疗的潜力。这一方向代表了从共价抑制剂向新一代选择性、可逆性分子转化的重要趋势。尽管具体数据尚未公开，但该系列研究可能为改善CLL患者安全性与耐药性管理提供新的治疗策略。局限在于目前缺乏详细临床结果，其效果与长期疗效仍需进一步验证。

---

## 8. 《白血病》杂志四十年回顾

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361661)
**期刊：** Leukemia
**PMID：** 41361661
**DOI：** 10.1038/s41375-025-02840-y

### 第一部分 原文与翻译

**英文原标题：** 40 years of LEUKEMIA.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文标题表明文章主要是对白血病专业期刊《Leukemia》创刊四十年来的发展历程进行回顾总结。预计内容可能涵盖该期刊在学科进步、研究热点演变以及学术传播影响方面的变化。此类综述通常通过编辑团队或学科权威的视角，梳理出版趋势与研究方向。文章的创新性在于提供历史性视野下的期刊学科贡献反思，但其局限在于缺乏原始实验或临床数据支撑。

---

## 9. 宿主常见基因组变异在儿童急性淋巴细胞白血病中的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361660)
**期刊：** Leukemia
**PMID：** 41361660
**DOI：** 10.1038/s41375-025-02804-2

### 第一部分 原文与翻译

**英文原标题：** Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.

> **英文摘要：**
> Childhood acute lymphoblastic leukemia (ALL) is a genetically heterogeneous disease, and while somatic alterations inform diagnosis and treatment stratification, germline variants - particularly common host genome variants - rarely influence clinical care. Over the past decade, various host genome variant studies have uncovered numerous common variants associated with ALL susceptibility, treatment efficacy, and toxicity risk. Yet, less than a handful have reached clinical implementation, with TPMT and NUDT15 variants being the only ones widely used clinically. Whether a variant can be readily translated into the clinical setting primarily depends on four features: (1) Phenotype severity, (2) phenotype rarity and the proportion of cases (overall or in subsets of patients) accounted for by genetic variants, (3) the application of the variant as an add-on clinical decision support tool, and (4) the availability, cost, and potential side effects of interventions and/or prophylaxis. Key barriers for such clinical translation include insufficient effect sizes, lack of replication across diverse populations, and lack of well-established treatment modification strategies. However, large-scale international collaborations can generate the necessary statistical power, including enabling more complex bioinformatic approaches, such as polygenic risk scores and more advanced machine learning strategies. In this review, we outline the necessary steps toward bridging the gap between genetic discovery and clinical practice.

> **中文摘要：**
> 儿童急性淋巴细胞白血病（ALL）是一种遗传异质性疾病。虽然体细胞改变可用于诊断和治疗分层，但种系变异——特别是宿主基因组中的常见变异——很少对临床实践产生直接影响。过去十年中，多项宿主基因组变异研究揭示了许多与ALL易感性、治疗疗效及毒性风险相关的常见变异。然而，真正进入临床应用的却寥寥无几，目前临床上广泛使用的仅有TPMT和NUDT15基因变异。某一变异能否较容易地应用于临床，主要取决于四个特征：（1）表型严重程度；（2）表型罕见性及由该遗传变异解释的病例比例（整体或部分患者亚群）；（3）该变异是否可作为附加的临床决策支持工具；以及（4）干预和/或预防措施的可获得性、成本及潜在副作用。此类临床转化的主要障碍包括效应量不足、不同人群中缺乏重复验证，以及缺乏成熟的治疗调整策略。然而，大规模国际合作可提供必要的统计效能，并推动更加复杂的生物信息学方法应用，如多基因风险评分及更高级的机器学习策略。在本综述中，作者概述了实现从遗传发现到临床实践转化所需的关键步骤。

### 第二部分 AI 大师评价

本研究综述了儿童急性淋巴细胞白血病中宿主常见基因组变异的作用及其临床转化现状。作者综合分析了变异影响临床应用的关键因素和现存障碍，并强调了国际协作与先进生物信息学方法在推动遗传发现转化中的重要性。文章内容系统、逻辑严谨，突出了从基础基因学到个体化医疗的跨越。其创新之处在于提出了实现临床转化的具体路径，但在可操作性与不同人群验证方面仍需进一步探索。

---

## 10. 代谢支持可防止放射诱导性黏膜炎中的铁死亡并保护黏膜。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361241)
**期刊：** Nature communications
**PMID：** 41361241
**DOI：** 10.1038/s41467-025-67214-5

### 第一部分 原文与翻译

**英文原标题：** Metabolic support protects mucosa from ferroptosis in radiation-induced mucositis.

> **英文摘要：**
> Ionizing radiation is effective in treating cancer but causes significant damage to the mucosa, thereby increasing patient discomfort, delaying therapy, and raising the risk of mortality. The underlying mechanisms of this damage remain poorly understood, and current treatments are largely palliative. In this study, ferroptosis was identified as the primary mode of cell death responsible for the radiation-induced depletion of oral mucosal epithelial cells. Notably, a compensatory phase was also discovered in the early stages following radiation exposure, during which fibroblasts provide crucial metabolic support. Specifically, fibroblasts supply polyamines that are readily absorbed by basal epithelial cells, protecting them from ferroptosis. Supplementation with polyamines was found to effectively prevent mucosal injury. These findings highlight the critical role of fibroblast-mediated metabolic support in protecting the oral mucosa from radiation-induced damage and offer insights into enhancing the body's intrinsic protective mechanisms against radiation-related diseases.

> **中文摘要：**
> 电离辐射在治疗癌症中具有有效性，但同时会对黏膜造成显著损伤，从而增加患者的不适感，延迟治疗进程，并提高死亡风险。此类损伤的潜在机制仍然知之甚少，且现有治疗主要以姑息为主。在本研究中，研究者鉴定出铁死亡是导致放射诱导的口腔黏膜上皮细胞耗竭的主要细胞死亡方式。值得注意的是，在辐射暴露后的早期阶段，还发现了一个代偿阶段，其中成纤维细胞提供关键的代谢支持。具体而言，成纤维细胞供应多胺，这些多胺可被基底上皮细胞迅速吸收，从而保护其免于铁死亡。补充多胺被证实能有效预防黏膜损伤。这些发现强调了成纤维细胞介导的代谢支持在防护口腔黏膜免受放射损伤中的关键作用，并为增强机体对放射相关疾病的内在防御机制提供了新见解。

### 第二部分 AI 大师评价

本研究揭示了放射诱导性黏膜炎中铁死亡的核心作用机制，并首次指出成纤维细胞通过代谢支持在保护口腔黏膜中的关键功能。通过发现多胺代谢在上皮细胞抗铁死亡中的作用，该研究提供了潜在的治疗干预靶点。其创新性在于将代谢支持与放射生物学相结合，深化了对放射损伤修复机制的理解。局限性在于模型仍需在人类临床条件下进一步验证。

---

## 11. 监测 NANOG 的快速降解揭示 UTP15 通过调控新生转录本维持多能性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361183)
**期刊：** Nature communications
**PMID：** 41361183
**DOI：** 10.1038/s41467-025-67018-7

### 第一部分 原文与翻译

**英文原标题：** Monitoring rapid degradation of NANOG reveals UTP15 maintains pluripotency by regulating nascent transcripts.

> **英文摘要：**
> Master transcription factors (MTFs) are key regulators in cell fate determination. However, an approach to profile MTF's direct transcriptional targets together with their associated RNA-binding proteins (RBPs), is still lacking. Here, we applied 5-ethynyluridine RNA metabolic labeling and click chemistry to map the dynamics of the transcriptional targets and the RBPs interacting with the newly transcribed RNAs upon acute NANOG degradation in mouse embryonic stem cells (mESCs). We identified UTP15, a classic rRNA-biogenesis regulator, acts as a key activator of pluripotency-associated gene transcription independently of rRNA biogenesis. Importantly, NANOG-regulated transcription enhances UTP15 binding to transcription start sites (TSSs), associated with increased Pol II binding and more active transcription. Moreover, UTP15 promotes the assembly of Pol II biomolecular condensates, thereby potentially driving pluripotency gene transcription. Collectively, our study uncovers a NANOG-nascent transcript-UTP15 regulatory axis to activate pluripotency gene transcription, providing a distinct approach for studying MTF's function during cell fate determination.

> **中文摘要：**
> 主转录因子（MTFs）是细胞命运决定中的关键调控因子。然而，目前仍缺乏一种能够同时描绘 MTF 直接转录靶标及其相关 RNA 结合蛋白（RBPs）的研究方法。在本研究中，我们采用 5‑炔基尿苷 RNA 代谢标记和点击化学技术，在小鼠胚胎干细胞（mESCs）中急性降解 NANOG 的情况下，描绘了转录靶基因及其与新转录 RNA 相互作用的 RBP 动态图谱。我们发现，经典的 rRNA 生物发生调控因子 UTP15 独立于 rRNA 生物发生，作为多能性相关基因转录的重要激活因子。重要的是，NANOG 调控的转录增强了 UTP15 与转录起始位点（TSSs）的结合，并伴随 Pol II 结合增加及转录活性提高。此外，UTP15 促进了 Pol II 生物分子凝聚体的组装，从而可能驱动多能性基因的转录。总体而言，我们的研究揭示了一个由 NANOG、新生转录本与 UTP15 构成的调控轴，用于激活多能性基因转录，并为研究 MTF 在细胞命运决定过程中的功能提供了一种新方法。

### 第二部分 AI 大师评价

该研究通过结合代谢标记与点击化学技术，在急性 NANOG 降解模型中系统刻画了主转录因子与 RNA 结合蛋白的动态相互作用。作者发现 UTP15 不仅参与 rRNA 生物发生，还独立介导多能性相关基因的转录激活，并与 Pol II 的结合及凝聚体组装密切相关。该研究首次提出 NANOG‑新生转录本‑UTP15 这一独特调控轴，揭示了维持胚胎干细胞多能性的新的分子机制。其创新性在于整合代谢标记、蛋白质组与转录动力学的多维分析，但仍需在体内模型中进一步验证其普适性与功能因果性。

---

## 12. 肝细胞癌切除后高复发风险患者中辅助使用本美司妥巴联合安罗替尼的研究：II期 ALTER-H006 临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361175)
**期刊：** Nature communications
**PMID：** 41361175
**DOI：** 10.1038/s41467-025-66342-2

### 第一部分 原文与翻译

**英文原标题：** Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006).

> **英文摘要：**
> This phase II study (ALTER-H006; NCT05111366) evaluates adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence (including ≥4 tumors, portal vein tumor thrombus [Vp1/2], or hepatic vein tumor thrombus [Vv1/2]) after hepatocellular carcinoma (HCC) resection. Primary endpoint is 1-year recurrence-free survival (RFS) rate. Secondary endpoints include overall survival (OS), 1-year OS rate, RFS, and safety. Median follow-up is 12.6 months. Among 37 patients enrolled, 1-year RFS rate is 59.7%, and median RFS is 15.6 months. Subgroups with Vp1/2 and Vv1/2 show median RFS of 18.2 months and not reached (NR), respectively. The longest recurrence-free duration is 25.9 months. Median OS is NR (1-year OS rate, 91.7%). Grade ≥3 treatment-related adverse events occur in 45.9% of patients, most commonly hypertension. No treatment-related deaths occur. Here, we show that adjuvant benmelstobart plus anlotinib is a feasible treatment option for HCC patients with high-risk recurrence after HCC resection, warranting confirmation in large-scale randomized clinical trials.

> **中文摘要：**
> 本 II 期研究（ALTER-H006；NCT05111366）评估了在肝细胞癌（HCC）切除后具有高复发风险（包括肿瘤数量≥4、门静脉癌栓 [Vp1/2] 或肝静脉癌栓 [Vv1/2]）患者中，辅助应用本美司妥巴联合安罗替尼的疗效。主要终点为 1 年无复发生存率（RFS）。次要终点包括总生存期（OS）、1 年 OS 率、RFS 以及安全性。中位随访时间为 12.6 个月。在纳入的 37 例患者中，1 年 RFS 率为 59.7%，中位 RFS 为 15.6 个月。含有 Vp1/2 及 Vv1/2 的亚组中，中位 RFS 分别为 18.2 个月和未达到（NR）。最长无复发持续时间为 25.9 个月。中位 OS 未达到（1 年 OS 率为 91.7%）。45.9% 的患者出现了 3 级及以上的治疗相关不良事件，最常见为高血压。未观察到治疗相关死亡事件。本研究表明，在 HCC 切除后高复发风险患者中，辅助应用本美司妥巴联合安罗替尼是一种可行的治疗选择，有待在大规模随机临床试验中进一步验证。

### 第二部分 AI 大师评价

该研究是一项针对肝细胞癌切除后高复发风险人群的 II 期临床试验，探讨本美司妥巴联合安罗替尼的辅助治疗价值。结果显示该方案具有较高的 1 年无复发生存率和良好的耐受性，且未见治疗相关死亡。研究提示免疫联合抗血管生成治疗可能改善高风险人群的预后，具有潜在应用价值。由于样本量有限且随访时间较短，仍需开展大样本随机对照研究以验证其长期疗效和安全性。

---

## 13. ERBB2信号通路驱动小细胞肺癌的免疫逃逸与免疫治疗耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361170)
**期刊：** Nature communications
**PMID：** 41361170
**DOI：** 10.1038/s41467-025-66800-x

### 第一部分 原文与翻译

**英文原标题：** ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer.

> **英文摘要：**
> Small cell lung cancer (SCLC) is characterized by its highly aggressive phenotype and dismal outcome. Despite the benefit of adding immune checkpoint blockade to standard chemotherapy, tumors acquire the ability to evade immunosurveillance and develop resistance. To investigate these underlying mechanisms, we perform high-dimensional profiling of human and murine SCLC specimens. In matched primary and metastatic human samples, we observe MHC-I loss in metastases, highlighting its role in immune evasion. Correspondingly, silencing MHC-I in SCLC cells drastically reduces immune infiltration and promotes metastasis in mice. Using mass spectrometry and phospho-tyrosine kinase analyses, we identify ERBB2 signaling as a suppressor of MHC-I and driver of immune-modulatory transcripts. Mechanistically, genetic and pharmacologic blockade of ERBB2 induces MHC-I in a STING-dependent manner and prevents immune evasion in autochthonous murine SCLC. Strikingly, combining ERBB2 inhibition with anti-PD-1 elicits profound synergistic responses in preclinical models, suggesting this combination for future clinical trials in SCLC patients.

> **中文摘要：**
> 小细胞肺癌（SCLC）以其高度侵袭性表型和极差的预后为特征。尽管在标准化疗方案中加入免疫检查点抑制可带来一定益处，但肿瘤仍会获得逃避免疫监视并产生耐药的能力。为探究其潜在机制，我们对人源及小鼠SCLC样本进行了高维组学分析。在配对的人类原发与转移样本中，我们观察到转移灶中MHC-I的丢失，提示其在免疫逃逸中的关键作用。相应地，在SCLC细胞中沉默MHC-I会显著减少免疫细胞浸润，并促进小鼠体内的转移。通过质谱和磷酸化酪氨酸激酶分析，我们发现ERBB2信号通路可抑制MHC-I表达，并驱动与免疫调控相关的转录程序。在机制上，ERBB2的基因或药理学阻断可通过依赖STING的途径诱导MHC-I的表达，从而防止自发性小鼠SCLC中的免疫逃逸。令人瞩目的是，在临床前模型中将ERBB2抑制与抗PD-1治疗联合使用可产生显著的协同反应，提示此组合方案可作为SCLC患者未来临床试验的候选策略。

### 第二部分 AI 大师评价

本文揭示了ERBB2信号通路在小细胞肺癌中通过抑制MHC-I表达而促进免疫逃逸与免疫治疗耐药的重要机制。研究采用多维度组学和跨物种模型验证，系统解析了从分子信号到免疫微环境的相互作用。其创新之处在于发现ERBB2阻断可依赖STING通路逆转免疫逃逸，并与抗PD-1治疗产生强烈协同效应，为难治性SCLC提供了新的治疗组合思路。研究的局限在于仍需进一步临床研究验证其安全性与疗效。

---

## 14. 搜索与去除型基因组编辑技术可实现基于 DNA 序列的细胞选择

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361167)
**期刊：** Nature communications
**PMID：** 41361167
**DOI：** 10.1038/s41467-025-66896-1

### 第一部分 原文与翻译

**英文原标题：** Search-and-remove genome editing allows selection of cells by DNA sequence.

> **英文摘要：**
> The selection of cells that have acquired a desired gene edit is often done by the introduction of additional genes that confer drug resistance or encode fluorophores. However, such marker genes can have unintended physiological effects and are not compatible with editing of single nucleotides. Here, we present SNIPE, a method that allows the marker-free selection of edited cells based on single nucleotide differences to unedited cells. SNIPE drastically enriches for cells, which have been precisely edited (median 7-fold). We validate the approach for 42 different edits using Cas9 or Cas12a in different cell types and species. We use it to enrich for combinations of substitutions that change missense mutations carried by all people today back to the ancestral state seen in Neandertals and Denisovans. We also show that it can be used to kill cultured tumor cells with aberrant genotypes and to repair heterozygous tumorigenic mutations.

> **中文摘要：**
> 对获得期望基因编辑的细胞进行筛选，通常依赖于引入赋予耐药性或表达荧光蛋白的附加基因。然而，这类标记基因可能产生意想不到的生理效应，并且不适用于单核苷酸水平的编辑。在此，我们提出了一种名为 SNIPE 的方法，可基于编辑细胞与未编辑细胞之间的单核苷酸差异，实现无标记的编辑细胞选择。SNIPE 能显著富集精确编辑过的细胞（中位值提高约 7 倍）。我们利用 Cas9 或 Cas12a 在不同细胞类型和物种中验证了 42 种不同编辑的可行性。我们还将其用于富集可将当代人群中普遍存在的错义突变恢复至尼安德特人和丹尼索瓦人祖先状态的替换组合。此外，我们展示了该方法可用于杀灭具有异常基因型的培养肿瘤细胞，以及修复杂合致瘤突变。

### 第二部分 AI 大师评价

该研究提出了 SNIPE 技术，一种能够在无外源标记基因的条件下，通过单核苷酸差异实现基因编辑细胞选择的新方法。其创新性在于结合搜索与去除机制，显著提高精确编辑细胞的富集效率。研究在不同物种及细胞类型中验证了其普适性，并展示了潜在应用，例如校正人类错义突变或特异性清除突变肿瘤细胞。该方法拓展了基因编辑后细胞筛选的策略，但其在体内应用推广及对复杂基因组环境的适应性仍需进一步研究。

---

## 15. 补液可拯救 Il22 小鼠免于致命的 Citrobacter rodentium 感染。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361166)
**期刊：** Nature communications
**PMID：** 41361166
**DOI：** 10.1038/s41467-025-67006-x

### 第一部分 原文与翻译

**英文原标题：** Rehydration rescues Il22 mice from lethal Citrobacter rodentium infection.

> **英文摘要：**
> Interleukin-22 (IL-22) is considered indispensable for host defence against Citrobacter rodentium, with 100% mortality of Il22 mice. While IL-22 promotes epithelial barrier integrity and production of antimicrobial peptides, the precise mechanism underlying lethality remains unclear. Here, we show that following C. rodentium infection Il22 mice succumb due to dehydration, rather than failure to control bacterial burden or regenerate damaged intestinal epithelium. Proteomic and gene expression analysis reveal greater enterocyte depletion in C. rodentium-infected Il22 mice, resulting in significant reductions in ion transporter abundances. We show that while not reducing bacterial load, improving the gut barrier integrity, or affecting immune responses, fluid therapy (FT) fully rescues Il22 mice by correcting systemic dehydration. Survival is associated with locally increased Reg3b, IL-17F and IL-10 levels, suggesting activation of compensatory pathways that potentially support recovery in the absence of IL-22. Recovered Il22 mice exhibit epithelial cell regeneration and tissue physiology similarly to C. rodentium-infected Il22 mice. These findings suggest that dehydration is the primary cause of mortality in Il22 mice and reveal that IL-22 prevent this outcome by preserving epithelial integrity and fluid-ion absorption. Importantly, this study underscores the necessity of incorporating supportive therapies into preclinical infection models to better reflect physiological settings and improve their relevance in modelling human disease.

> **中文摘要：**
> 白细胞介素-22（IL-22）被认为是宿主抵御 Citrobacter rodentium 感染所必需的，Il22 基因缺失小鼠在感染中死亡率为 100%。尽管 IL-22 能促进上皮屏障完整性及抗菌肽的产生，但其导致致死性的确切机制尚不清楚。在本研究中，我们发现，感染 C. rodentium 后，Il22 小鼠的死亡是由于脱水，而非无法控制细菌负荷或无法再生受损的肠上皮。蛋白质组学和基因表达分析显示，感染 C. rodentium 的 Il22 小鼠中肠上皮细胞损失更为严重，导致离子转运蛋白丰度显著下降。我们进一步表明，尽管液体治疗（FT）并未降低细菌负荷、改善肠屏障完整性或影响免疫反应，但通过纠正全身性脱水，它能使 Il22 小鼠完全存活。存活与 Reg3b、IL-17F 和 IL-10 水平在局部的升高有关，提示补偿性通路的激活可能在缺乏 IL-22 时支持恢复。康复的 Il22 小鼠在上皮细胞再生及组织生理方面与 C. rodentium 感染小鼠相似。这些发现表明，脱水是 Il22 小鼠死亡的主要原因，并揭示了 IL-22 通过维持上皮完整性与液体-离子吸收来预防该结果。重要的是，本研究强调了在前临床感染模型中引入支持性治疗的必要性，以更好地反映生理环境并提高其在人类疾病建模中的相关性。

### 第二部分 AI 大师评价

本研究通过动物感染模型揭示了 IL-22 缺失小鼠对 Citrobacter rodentium 感染的致死机制，指出死亡的关键原因在于脱水而非细菌负荷失控。研究采用蛋白质组与基因表达分析等多层手段，阐明 IL-22 缺失导致离子转运功能下降。补液治疗成功逆转死亡结局，提示生理补偿途径在宿主防御中具有核心作用。该发现创新性地从生理角度重新审视免疫因子功能，为前临床感染模型的优化提供了重要启示，但机制层面仍需深入探讨液体稳态与免疫信号的交互关系。

---

## 16. RNASEH2C通过增强TRAF3IP1介导溶酶体中RAI14的降解，从而抑制巨噬细胞抗原呈递并促进肝癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361104)
**期刊：** Cell death & disease
**PMID：** 41361104
**DOI：** 10.1038/s41419-025-08305-5

### 第一部分 原文与翻译

**英文原标题：** RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer.

> **英文摘要：**
> Macrophage antigen presentation is crucial for adaptive immunity and maintaining immune balance, including anti-infection, anti-tumor, and inflammation regulation. However, its role in tumor immunomodulation is less understood compared to macrophage polarization. This study explored how Rnaseh2c macrophages influence hepatocellular carcinoma (HCC) progression using in vitro cell models and mouse tumor models. Single-cell RNA sequencing, immunoblotting, immunofluorescence, immunoprecipitation, and flow cytometry analysis were employed to examine RNASEH2C's impact on macrophage antigen presentation. Our results indicated that Rnaseh2c macrophages, which were non-polarized, promoted HCC growth by inhibiting antigen presentation. RNASEH2C facilitated lysosomal degradation of RAI14 by enhancing TRAF3IP1 expression and suppressing the mTOR pathway, with HSC70 and CMTM6 playing opposing roles in RAI14 degradation. RAI14, a skeleton protein, facilitated the macropinocytosis of MHC II molecules and tumor-associated antigen, thus activating Th1 cells in HCC. In conclusion, our study revealed how RNASEH2C mediated RAI14's lysosomal degradation, offering potential targets and strategies for HCC immunotherapy.

> **中文摘要：**
> 巨噬细胞的抗原呈递对于获得性免疫及维持免疫平衡至关重要，包括抗感染、抗肿瘤以及炎症调控。然而，与巨噬细胞极化相比，其在肿瘤免疫调节中的作用尚不十分清楚。本研究利用体外细胞模型和小鼠肿瘤模型，探讨了Rnaseh2c巨噬细胞对肝细胞癌（HCC）进展的影响。研究采用单细胞RNA测序、免疫印迹、免疫荧光、免疫共沉淀和流式细胞术等方法分析RNASEH2C对巨噬细胞抗原呈递的影响。结果表明，非极化状态的Rnaseh2c巨噬细胞通过抑制抗原呈递促进了HCC的生长。RNASEH2C通过增强TRAF3IP1的表达并抑制mTOR通路，促进RAI14在溶酶体中的降解，而HSC70和CMTM6在RAI14降解中发挥相反作用。RAI14作为一种骨架蛋白，促进了MHC II分子和肿瘤相关抗原的吞饮作用，从而在HCC中激活Th1细胞。总之，本研究揭示了RNASEH2C介导RAI14的溶酶体降解机制，为HCC免疫治疗提供了潜在的靶点与策略。

### 第二部分 AI 大师评价

该研究揭示RNASEH2C通过调控TRAF3IP1促进RAI14在溶酶体中的降解，从而抑制巨噬细胞抗原呈递并推动肝细胞癌的发生发展。研究运用单细胞转录组、蛋白层面验证及功能实验等多手段，系统解析了分子间相互作用与免疫调控机制。发现RAI14在抗原摄取及Th1激活中的关键作用，拓展了对巨噬细胞在肿瘤免疫微环境中作用的认识。该工作具有较强的机制创新性，但仍需进一步验证其在临床免疫治疗中的可行性与普适性。

---

## 17. 食管腺癌的分子分层：对预后与治疗策略的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361079)
**期刊：** Oncogene
**PMID：** 41361079
**DOI：** 10.1038/s41388-025-03650-3

### 第一部分 原文与翻译

**英文原标题：** Molecular stratification of esophageal adenocarcinoma: implications for prognosis and treatment strategy.

> **英文摘要：**
> Genome-wide molecular profiling has emerged as a promising approach for advancing the clinical management of esophageal adenocarcinoma (EAC), with the potential to improve prognostic accuracy and enable more personalized treatment strategies. In this review, we summarize current evidence from genomic and epigenomic EAC stratification studies, highlighting the proposed molecular subtypes and evaluating their clinical relevance. We discuss how these subclassifications may inform disease outcomes, refine patient selection for specific therapies and uncover new treatment opportunities aligned with tumor molecular profiles. Additionally, we explore molecular subtypes associated with Barrett's esophagus, a precursor lesion of EAC, and consider how these insights can help elucidate the mechanisms underlying EAC development. Such understanding may inform improved strategies for early tumor detection, risk stratification and prevention, ultimately aiming to reduce the burden of EAC. We also address the current challenges limiting the clinical application of these molecular classifiers, including restricted sample availability, insufficient validation and the difficulty of translating genome-wide findings into practical and clinical useful biomarkers. Integrating molecular subtyping into clinical workflows is a key step toward precision medicine in EAC, with the goal of enhancing treatment response rates and patient outcomes. Future advances will require collaborative efforts and robust clinical validation in large prospective studies to ensure that molecular stratification strategies can be effectively translated into improved management of EAC.

> **中文摘要：**
> 全基因组水平的分子谱分析已成为推进食管腺癌（EAC）临床管理的一种前景广阔的方法，具有提高预后准确性并实现更个体化治疗策略的潜力。在本综述中，我们总结了现有关于EAC的基因组及表观基因组分层研究的证据，重点介绍已提出的分子亚型，并评估其临床相关性。我们讨论了这些亚分类如何帮助预测疾病结局、优化患者针对特定疗法的选择，以及揭示与肿瘤分子特征相匹配的新治疗机会。此外，我们探讨了与EAC前病变巴雷特食管相关的分子亚型，并考虑这些发现如何有助于阐明EAC发生的潜在机制。这种理解可能推动改进的早期肿瘤检测、风险分层及预防策略，从而最终降低EAC的疾病负担。我们还讨论了目前限制这些分子分类器临床应用的挑战，包括样本数量有限、验证不足，以及将全基因组发现转化为具有临床实用性的生物标志物的困难。将分子分型整合到临床流程中是实现EAC精准医学的重要一步，旨在提高治疗反应率并改善患者预后。未来的进展需要协作努力以及在大型前瞻性研究中的稳健临床验证，以确保分子分层策略能够真正转化为EAC管理的改进。

### 第二部分 AI 大师评价

本综述旨在概述食管腺癌的分子分层研究进展，系统总结基因组与表观基因组层面的证据，并探讨其对预后和治疗的指导意义。文章的核心创新在于强调分子亚型在临床决策中的潜在价值，并提出其与巴雷特食管相关的病理联系。该研究凸显了分子分型在精准医学中的应用前景，同时指出了样本量、验证及临床转化等现实挑战。整体而言，本文为EAC分子分层的临床应用提供了重要综述与未来研究方向。

---

## 18. circSETD3 通过上调 PDIA6 减弱内质网应激诱导的自噬与凋亡，从而赋予鼻咽癌放射治疗抗性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361078)
**期刊：** Oncogene
**PMID：** 41361078
**DOI：** 10.1038/s41388-025-03652-1

### 第一部分 原文与翻译

**英文原标题：** circSETD3 confers radiotherapy resistance in nasopharyngeal carcinoma by attenuating ER stress-induced autophagy and apoptosis via PDIA6 upregulation.

> **英文摘要：**
> Nasopharyngeal carcinoma (NPC) is a malignant tumor of the head and neck with a high prevalence in Southeast Asia. Although radiotherapy remains the primary treatment modality, resistance to radiation in a subset of patients with advanced-stage disease significantly limits therapeutic outcomes, and the underlying molecular mechanisms remain poorly understood. In this study, we identified the circular RNA circSETD3 as a critical regulator of radioresistance in NPC. Functional assays in both in vitro and in vivo models demonstrated that circSETD3 enhances radioresistance by suppressing autophagy and apoptosis. Mechanistically, circSETD3 binds to the 3' untranslated region (3'UTR) of PDIA6 mRNA, stabilizing the transcript and increasing PDIA6 protein expression and its localization to the endoplasmic reticulum (ER). Elevated PDIA6 promotes the refolding of radiation-induced misfolded proteins, maintains ER proteostasis, and suppresses the unfolded protein response (UPR). This alleviation of ER stress reduces radiation-induced autophagy and apoptosis, ultimately enhancing NPC cell survival under radiotherapeutic stress. Together, these findings reveal a pivotal role for circSETD3 in promoting NPC radioresistance via PDIA6-mediated modulation of endoplasmic reticulum stress, and they provide a novel mechanistic framework and promising therapeutic target for improving radiotherapy efficacy in NPC.

> **中文摘要：**
> 鼻咽癌（NPC）是一种发生于头颈部的恶性肿瘤，在东南亚地区的发病率较高。尽管放射治疗仍然是主要的治疗手段，但部分晚期患者出现的放射抗性显著限制了治疗效果，而其潜在的分子机制仍不清楚。在本研究中，我们鉴定出环状 RNA circSETD3 是鼻咽癌放射抗性的关键调控因子。体内外功能实验表明，circSETD3 通过抑制自噬和凋亡增强放射抗性。从机制上看，circSETD3 可结合 PDIA6 mRNA 的 3′ 非翻译区（3′UTR），稳定其转录本并增加 PDIA6 蛋白的表达及其在内质网（ER）中的定位。升高的 PDIA6 促进放射诱导的错误折叠蛋白重新折叠，维持内质网蛋白稳态，并抑制未折叠蛋白反应（UPR）。这种内质网应激的缓解减少了放射诱导的自噬和凋亡，最终提高了鼻咽癌细胞在放射应激下的存活率。总体而言，这些发现揭示了 circSETD3 通过 PDIA6 介导的内质网应激调控在促进鼻咽癌放射抗性中的关键作用，并为改进鼻咽癌放疗效果提供了新的机制框架和潜在治疗靶点。

### 第二部分 AI 大师评价

该研究揭示了 circSETD3 在鼻咽癌放射抗性形成中的关键作用，系统阐明了其通过上调 PDIA6 稳定 mRNA 并缓解内质网应激，从而抑制自噬与凋亡、提高细胞存活率的机制。研究方法结合了体内外实验，证据充分。其创新之处在于发现环状 RNA 调控 ER 应激通路的新机制。该研究为克服放射抗性提供了潜在的分子靶点，但仍需进一步验证其临床可行性及安全性。

---

## 19. 癌症糖酵解与代谢中的长链非编码RNA：机制与转化机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361062)
**期刊：** Cell death & disease
**PMID：** 41361062
**DOI：** 10.1038/s41419-025-08289-2

### 第一部分 原文与翻译

**英文原标题：** Long non-coding RNAs in cancer glycolysis and metabolism: mechanisms and translational opportunities.

> **英文摘要：**
> Long non-coding RNAs (lncRNAs) have emerged as critical regulators of cancer metabolism, particularly in the reprogramming of glycolysis that supports tumor growth and survival. Once considered non-functional genomic "noise", lncRNAs influence metabolic adaptation by modulating glycolytic enzymes, transcription factors, and signaling pathways, while also shaping the tumor microenvironment through immune and stromal interactions. In addition, lncRNA-encoded micropeptides provide an extra layer of metabolic control, underscoring their functional diversity. These features indicate lncRNAs as promising diagnostic biomarkers and therapeutic targets, particularly in the context of personalized cancer treatments. RNA-based therapies demonstrate preclinical efficacy in targeting glycolytic lncRNA and reversing drug resistances. Nonetheless, challenges remain, including delivery specificity, off-target effects, and limited clinical validation. Advances in single-cell multi-omics, spatial transcriptomics, and artificial intelligence may offer new avenues to overcome these challenges. Collectively, lncRNAs represent both mechanistic drivers of glycolysis and promising targets for innovative diagnostic and therapeutic strategies in cancer.

> **中文摘要：**
> 长链非编码RNA（lncRNA）已成为癌症代谢的关键调控因子，尤其在重编程糖酵解以支持肿瘤生长和存活方面发挥重要作用。曾被认为是无功能的基因组“噪音”，lncRNA通过调控糖酵解酶、转录因子及信号通路来影响代谢适应，同时还通过免疫与基质相互作用塑造肿瘤微环境。此外，lncRNA编码的微肽提供了额外层次的代谢控制，突显其功能多样性。这些特征表明，lncRNA是潜在的诊断生物标志物和治疗靶点，尤其在个体化癌症治疗中具有前景。基于RNA的疗法在靶向糖酵解相关lncRNA和逆转耐药性方面已显示出临床前疗效。然而，仍存在诸如递送特异性、脱靶效应及临床验证有限等挑战。单细胞多组学、空间转录组学及人工智能的进展或将为克服这些障碍提供新途径。总体而言，lncRNA既是糖酵解的机制驱动者，也是癌症中创新诊断与治疗策略的有前景靶点。

### 第二部分 AI 大师评价

该研究综述了长链非编码RNA在癌症糖酵解和代谢重塑中的作用机制与转化潜力，强调其在酶调控、信号通路及肿瘤微环境塑造中的多层作用。文章指出lncRNA不仅是代谢重编程的驱动因子，也是可用于个体化治疗的潜在生物标志物和干预靶点。作者还讨论了RNA治疗在机制研究和药物耐受逆转中的前景，并识别出递送及脱靶等现实挑战。整体上，该文在连接代谢调控与RNA治疗创新层面具有较高的前瞻性与整合价值。

---

## 20. 基于外周血单细胞免疫特征的微小侵袭性肺结节精准诊断

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360981)
**期刊：** Nature communications
**PMID：** 41360981
**DOI：** 10.1038/s41467-025-65930-6

### 第一部分 原文与翻译

**英文原标题：** Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral blood.

> **英文摘要：**
> Early detection of lung cancer is crucial for improving patient outcomes. However, accurately diagnosing invasive pulmonary nodules and predicting tumor invasiveness remain major clinical challenges. Given the established role of immune dysfunction in cancer development, we hypothesize that peripheral immune profiling could provide a strategy for managing pulmonary nodules. In this multi-center, prospective study, we combine peripheral immune profiling via mass cytometry with machine learning algorithms to develop an integrated pulmonary nodule management platform. This platform accurately distinguishes invasive from non-invasive pulmonary nodules (AUC = 0.952), outperforming established clinical and radiomics-based models. Furthermore, it effectively predicts tumor invasiveness, differentiating minimally invasive from invasive adenocarcinoma (AUC = 0.949), thereby offering valuable guidance for surgical decision-making. In conclusion, the platform demonstrates substantial clinical utility and holds significant promise as a precision tool for future management of pulmonary nodules.

> **中文摘要：**
> 早期发现肺癌对于改善患者预后至关重要。然而，准确诊断侵袭性肺结节并预测肿瘤侵袭性仍是临床上的主要挑战。鉴于免疫功能障碍在癌症发生中的关键作用，我们假设外周免疫谱分析可为肺结节的管理提供一种策略。在这项多中心前瞻性研究中，我们将基于质谱流式细胞术的外周免疫谱分析与机器学习算法相结合，开发了一个集成的肺结节管理平台。该平台能够准确区分侵袭性与非侵袭性肺结节（AUC = 0.952），其性能优于既有的临床模型和影像组学模型。此外，该平台还能有效预测肿瘤的侵袭性，区分微侵袭性与侵袭性腺癌（AUC = 0.949），从而为外科决策提供有价值的指导。综上所述，该平台展现出显著的临床实用性，有望成为未来肺结节精准管理的重要工具。

### 第二部分 AI 大师评价

本研究旨在通过融合外周血单细胞免疫特征与机器学习算法，实现对微小侵袭性肺结节的精准诊断与侵袭性预测。研究采用多中心前瞻性设计，并建立了高准确度的集成管理平台，性能优于传统临床与影像组学模型。其主要创新在于将免疫系统状态纳入肺结节风险评估框架，为术前决策提供客观依据。尽管结果令人鼓舞，但仍需在更大规模人群及不同疾病背景下进一步验证。

---

## 21. 药理性激活 p53 在血管生成萌芽过程中诱导内皮细胞命运的剂量依赖性改变

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360924)
**期刊：** Cell death & disease
**PMID：** 41360924
**DOI：** 10.1038/s41419-025-08292-7

### 第一部分 原文与翻译

**英文原标题：** Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

> **英文摘要：**
> The cell cycle is a key regulator of endothelial cell specification into tip and stalk cell phenotypes, which are essential for angiogenesis in both normal development and pathological conditions. While the tumor suppressor p53 is known to regulate the cell cycle and influence cell fate, its role in modulating the cell fate of these phenotypes remains unclear. Using non-genotoxic small molecule and stapled peptide compounds to pharmacologically activate p53 via MDM2 inhibition, we demonstrate that graded levels of p53 induce distinct cellular fates in normal endothelial cells. Low levels of p53 induce reversible cell cycle arrest by reducing DNA replication, while high levels induce senescence and cell death. Surprisingly, all tested levels of p53 activation reduced the growth of venous blood vessels in vitro and in zebrafish embryo models. This reduction in sprouting may stem from distinct cellular responses in tip-like and non-tip-like cells to pharmacological p53 activation: low p53 levels primarily reduced proliferation in non-tip-like cells, whereas high levels decreased the frequency of tip-like cells and the expression of genes associated with tip and stalk cell identities. Our findings show for the first time that pharmacological p53 activation modulates endothelial cell fate in a dose-dependent manner during sprouting angiogenesis. They also highlight the potential of using graded p53 modulation as a therapeutic strategy to target abnormal tip or stalk cell development in pathological angiogenesis, such as in cancer.

> **中文摘要：**
> 细胞周期是调控内皮细胞分化为尖端细胞和柄状细胞表型的关键因素，而这些表型在正常发育和病理状态下的血管生成中都至关重要。虽然已知肿瘤抑制因子 p53 能调节细胞周期并影响细胞命运，但其在这些表型命运调控中的作用仍不明确。我们利用通过抑制 MDM2 的非基因毒性小分子和主链固定肽类化合物实现对 p53 的药理性激活，证明了在正常内皮细胞中，不同梯度水平的 p53 会诱导不同的细胞命运。低水平的 p53 通过减少 DNA 复制引发可逆性的细胞周期停滞，而高水平的 p53 则会诱导细胞衰老和死亡。令人意外的是，无论何种水平的 p53 激活均在体外及斑马鱼胚胎模型中减少了静脉血管的生长。这种萌芽血管减少可能源于尖端样细胞与非尖端样细胞对 p53 药理性激活的差异性反应：低水平 p53 主要抑制非尖端样细胞的增殖，而高水平 p53 则减少尖端样细胞的比例及与尖端和柄状细胞特征相关基因的表达。我们的研究首次表明，在血管生成萌芽过程中，药理性激活 p53 以剂量依赖的方式调控内皮细胞命运。同时，本研究也突出了通过精细调节 p53 水平以靶向病理性血管生成中异常尖端或柄状细胞发育的潜在治疗策略价值，例如在癌症背景下。

### 第二部分 AI 大师评价

该研究旨在阐明 p53 在血管生成过程中通过剂量依赖机制调控内皮细胞命运的作用。作者采用非基因毒性方式药理性激活 p53，结合体外培养和斑马鱼模型，揭示了低水平 p53 抑制增殖而高水平诱导衰老与死亡的双相效应。研究发现不同程度的 p53 激活均削弱了血管萌芽，这为理解 p53 与血管生成之间的联系提供了新视角。其创新之处在于首次提出药理性 p53 激活可剂量调控内皮命运，但仍需进一步验证其在病理环境中的长期可控性与安全性。

---

## 22. 多条代谢途径的整合促进了活性微生物岩中高效的碳沉淀速率。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360806)
**期刊：** Nature communications
**PMID：** 41360806
**DOI：** 10.1038/s41467-025-66552-8

### 第一部分 原文与翻译

**英文原标题：** Integration of multiple metabolic pathways supports high rates of carbon precipitation in living microbialites.

> **英文摘要：**
> Microbialites are lithifying microbial mats that form multi-layered structures via biological carbon (C) uptake and carbonate precipitation. Here we relate C uptake and precipitation rates to taxonomic diversity and functional capacity of bacterial communities in supratidal freshwater microbialites. Diel assays and analysis of functional gene capacity reveal that photosynthesis is bolstered by light-independent, biological C uptake mechanisms, including biomineralization and chemoautotrophy. Through integration of these mechanisms, microbialites can capture inorganic C over a 24-hour cycle at a rate of 7-12 g C m 24 h. Notably, up to 87 % of the C taken up is precipitated as inorganic carbon, capturing 2.4 - 4.3 kg C m year. Based on observed porosity and laboratory-based accretion rates, this equates to 13-23 mm of vertical calcium carbonate accumulation per year. Hence, contemporary microbialites provide a highly effective biological mechanism to precipitate dissolved CO as geologically stable carbonate mineral deposits.

> **中文摘要：**
> 微生物岩是能够发生岩化的微生物席，通过生物吸收碳（C）并沉淀碳酸盐形成多层结构。本文将碳吸收与沉淀速率与超潮带淡水微生物岩中细菌群落的分类多样性及功能潜能进行了关联分析。昼夜实验及功能基因能力分析显示，光合过程受到光非依赖性生物碳吸收机制（包括生物矿化和化能自养）的增强。通过整合这些机制，微生物岩在24小时周期内可捕获无机碳，速率为7–12克碳每平方米每天。值得注意的是，所吸收碳的高达87%以无机碳的形式沉淀，可年均固定2.4–4.3千克碳每平方米。根据观测的孔隙率和实验室测定的积累速率推算，这相当于每年13–23毫米的垂直碳酸钙积累。因此，当代微生物岩提供了一种高效的生物学机制，将溶解的二氧化碳以地质稳定的碳酸盐矿物形式进行沉淀固定。

### 第二部分 AI 大师评价

本研究旨在揭示微生物岩中多种代谢途径整合如何促进高效碳沉淀。作者通过昼夜实验和功能基因分析，发现除光合作用外，生物矿化与化能自养等光非依赖性机制也在碳吸收中发挥重要作用。结果显示，微生物岩可实现显著的无机碳固定和碳酸钙沉积速率，指示其在地质碳封存方面的重要生态功能。其创新在于将代谢网络与沉积过程联系起来，但仍需进一步研究环境因素对不同代谢机制贡献的影响。

---

## 23. 通过源自细胞突起的细胞外囊泡进行蛋白递送实现高效的细胞转化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360804)
**期刊：** Nature communications
**PMID：** 41360804
**DOI：** 10.1038/s41467-025-66351-1

### 第一部分 原文与翻译

**英文原标题：** Efficient cellular transformation via protein delivery through the protrusion-derived extracellular vesicles.

> **英文摘要：**
> Extracellular vesicles (EVs) mediate the transfer of intracellular proteins from producer to recipient cells. EVs originate either from plasma membrane protrusions or endosomes, with endosome-derived EVs being extensively studied and engineered. However, the efficiency and functionality of protein transfer via both types of EVs remain poorly understood. Here, we demonstrate that natural EVs derived from cell protrusions dependent on the I-BAR protein MIM, rather than from endosomes, deliver the functional small GTPase Rac1 protein at levels similar to microinjection. Rac1-containing EVs are internalized via endocytosis, trafficked through endosomal compartments, and subsequently released into the cytosol, where they enhance cell motility. To evaluate broader applicability, the genome-editing protein Cas12f is packaged into protrusion-derived EVs by MIM and endosome-derived EVs by endosomal tetraspanin CD63. Notably, protrusion-derived EVs deliver Cas12f with significantly higher efficiency than endosome-derived EVs, highlighting their superior capability for functional protein transfer. Our findings establish the protrusion-derived EVs as a powerful platform for the efficient and bioactive delivery of both native and engineered proteins, expanding the EV-based therapeutic strategies.

> **中文摘要：**
> 细胞外囊泡（EVs）介导了细胞内蛋白质从分泌细胞向受体细胞的转运。EVs 可来源于质膜突起或内体，其中源自内体的 EVs 已被广泛研究与工程化。然而，通过这两种类型的 EVs 进行蛋白转运的效率和功能性仍知之甚少。在本研究中，我们证明了依赖 I-BAR 蛋白 MIM 的、来源于细胞突起的天然 EVs，而非来源于内体的 EVs，能够以与显微注射相当的水平递送具有功能的小 GTP 酶 Rac1 蛋白。含 Rac1 的 EVs 通过内吞作用被内化，经由内体区室运输，随后释放入细胞质中，从而增强细胞运动能力。为了评估该机制的更广泛适用性，研究者将基因编辑蛋白 Cas12f 分别由 MIM 包装入突起来源的 EVs，以及由内体四跨膜蛋白 CD63 包装入内体来源的 EVs。值得注意的是，突起来源的 EVs 在递送 Cas12f 方面的效率显著高于内体来源的 EVs，突显了其在功能性蛋白转运方面的优越能力。本研究发现确立了突起来源 EVs 作为一种高效且具生物活性的蛋白递送平台，为扩展基于 EV 的治疗策略提供了新的方向。

### 第二部分 AI 大师评价

该研究旨在阐明细胞外囊泡不同来源在蛋白递送方面的效率差异。作者通过比较突起来源与内体来源 EVs，发现前者在递送活性蛋白（如 Rac1 与 Cas12f）方面显著优越，机制涉及内吞与胞质释放过程。研究不仅揭示了突起来源 EVs 的独特生物学功能，还提出了其在蛋白递送与治疗应用中的潜力。其创新性在于发现了一种自然高效的EV递送平台，但仍需进一步研究其在体内环境中的稳定性与靶向性。

---

## 24. 抑制B细胞可增强STING激动剂或免疫检查点阻断在肝细胞癌中的疗效。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360802)
**期刊：** Nature communications
**PMID：** 41360802
**DOI：** 10.1038/s41467-025-66581-3

### 第一部分 原文与翻译

**英文原标题：** Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma.

> **英文摘要：**
> Most patients with hepatocellular carcinoma (HCC) develop resistance to immune checkpoint blockade (ICB) or STING agonists despite their immune-stimulating activities. Here, we identify increased intratumoral B-cell infiltration as a mediator of acquired resistance. In HCC models with liver fibrosis in male mice, anti-PD-1 ICB or the STING agonist BMS-986301 increase intratumoral B-cell infiltration, circulating IL-10, and TIM-1 B-cells, promoting tertiary lymphoid structure formation. B-cell depletion combined with ICB or STING agonism improves survival, and STING agonism inhibits distant metastasis. In addition, co-targeting STING and TIM-1 enhances B-cell differentiation and antigen presentation, reduces intratumoral TIM-1 B-cells, and increases CD86 and MHC class II expression, thereby augmenting CD8 T-cell-mediated anti-tumor immunity. These findings reveal that B-cells contribute to ICB and STING therapy resistance in HCC, and that B-cell depletion or TIM-1 blockade can overcome acquired resistance to these immunotherapies.

> **中文摘要：**
> 尽管免疫检查点阻断（ICB）或STING激动剂具有免疫刺激活性，但大多数肝细胞癌（HCC）患者会产生耐药性。在本研究中，我们发现肿瘤内B细胞浸润增加是获得性耐药的介导因素。在具有肝纤维化的雄性小鼠HCC模型中，抗PD-1 ICB或STING激动剂BMS-986301可增加肿瘤内B细胞浸润、循环IL-10及TIM-1阳性B细胞，促进三级淋巴结构的形成。B细胞清除与ICB或STING激动剂联合治疗可改善生存率，而STING激动剂还可抑制远处转移。此外，同时靶向STING和TIM-1可增强B细胞分化和抗原呈递功能，减少肿瘤内TIM-1阳性B细胞，并增加CD86和MHC II类分子的表达，从而增强CD8 T细胞介导的抗肿瘤免疫反应。这些研究结果揭示了B细胞在HCC中对ICB和STING治疗耐药的作用，并提示通过B细胞清除或TIM-1阻断可克服这些免疫疗法的获得性耐药。

### 第二部分 AI 大师评价

该研究针对肝细胞癌免疫治疗耐药问题，揭示了B细胞在ICB和STING疗法耐药中的关键作用。作者通过小鼠模型和机制研究发现，B细胞浸润及TIM-1阳性B细胞促进免疫耐受，而去除B细胞或阻断TIM-1可增强抗肿瘤效应。研究创新性地将B细胞作为免疫治疗耐药的新靶点，为提高免疫治疗疗效提供了新策略。其局限性在于模型主要基于动物实验，临床可转化性尚需进一步验证。

---

## 25. 基于小型生物相容性分子的高有序大孔氢键有机框架

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360801)
**期刊：** Nature communications
**PMID：** 41360801
**DOI：** 10.1038/s41467-025-67123-7

### 第一部分 原文与翻译

**英文原标题：** Highly ordered macroporous hydrogen-bonded organic frameworks based on small biocompatible molecules.

> **英文摘要：**
> Template method offers a promising strategy for synthesizing large pore inaccessible through traditional molecular design. However, this approach has not yet been successfully implemented in molecular assemblies based on weak non-covalent interactions (NCIs), mainly because the assemblies often deviate from original structures during template-assisted syntheses, and the resulting porous structures lack the robustness to survive upon template removal. In this work, we address these challenges through choosing small biocompatible building blocks featuring multiple hydrogen-bonded sites and extensive π conjugation, enabling self-assembly into desired structure in the presence of templates and ensure structural integration upon template removal. As a result, the transformation from densely packed hydrogen-bonded crystalline materials to macroporous structure, referred to as hydrogen-bonded organic frameworks (HOFs), becomes achievable. This strategy facilitates the fabrication of highly ordered materials in single-crystal form with high physiological stability, and enhanced mass transfer. Importantly, it greatly broadens the HOF library to small, affordable, low-toxic, and clinically applicable molecules, making HOFs promising biocompatible porous substrates for bio-related applications such as enzyme immobilization. Herein, we successfully loaded trypsin into macroporous HOFs, which function as effective cellular scaffolds and promote the differentiation of peripheral blood mononuclear cells into fibrocytes, demonstrating their promising potential for biologic applications.

> **中文摘要：**
> 模板法为合成传统分子设计难以获得的大孔结构提供了一种有前景的策略。然而，这一方法尚未在基于弱非共价相互作用（NCI）的分子组装中成功实现，主要原因在于组装体在模板辅助合成过程中常常偏离原始结构，且生成的多孔结构在去除模板后缺乏足够的稳健性而难以保持。本文通过选择具有多重氢键作用位点和广泛π共轭的小型生物相容性构筑单元，解决了这些挑战，使其在模板存在下能够自组装形成目标结构，并在去模板后保持结构完整性。因此，从密堆积氢键结晶材料到大孔结构（即氢键有机框架，HOFs）的转变成为可能。该策略促进了具有高生理稳定性和增强质量传递性能的高有序单晶材料的制备。更为重要的是，它极大地扩展了HOF材料库，使其涵盖小型、可负担、低毒且具临床应用潜力的分子，从而使HOF成为酶固定化等生物相关应用中有前景的生物相容多孔基质。在此基础上，我们成功将胰蛋白酶负载至大孔HOF中，该体系可作为有效的细胞支架，促进外周血单个核细胞向成纤维细胞分化，显示出其在生物学应用方面的潜在前景。

### 第二部分 AI 大师评价

本研究提出了一种利用小型生物相容性分子构筑高有序大孔氢键有机框架（HOFs）的创新策略。通过引入模板法与多氢键位点、π共轭分子的结合，成功实现了从致密晶体向稳健大孔结构的转变。所得单晶HOF具有优异的生理稳定性和良好的质量传递性能，并可作为酶固定或细胞支架使用，展示出广泛的生物医学应用潜力。该工作显著拓宽了HOF材料库，为生物兼容性多孔材料的分子设计提供了新思路，但其在规模化制备与长期生物环境稳定性方面仍需进一步验证。

---

## 26. 母乳喂养的血浆代谢组学特征及其与心脏代谢疾病风险的关系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360798)
**期刊：** Nature communications
**PMID：** 41360798
**DOI：** 10.1038/s41467-025-65977-5

### 第一部分 原文与翻译

**英文原标题：** Plasma metabolomic signature of breastfeeding and risk of cardiometabolic diseases.

> **英文摘要：**
> Breastfeeding is inversely associated with cardiometabolic disease incidence in prospective studies; however, the metabolic pathways underlying these associations remain largely unknown. Here, we derive a plasma metabolomic score of lifetime total duration of breastfeeding using elastic net regularized regression in Nurses' Health Studies (n = 4349) and replicate in the Women's Health Initiative (n = 2088). Data include 181 untargeted plasma metabolites profiled by liquid chromatography mass spectrometry using blood samples collected in mid-life, and self-reported lifetime total duration of breastfeeding. We then examine the associations between the metabolite-based breastfeeding score and risk of T2D and CVD using multivariable Cox regression models and replicated in two external cohorts. The metabolite-based breastfeeding score comprised of 5 metabolites (i.e., C54:2 triglyceride, C56:2 triglyceride, C56:3 triglyceride, cotinine, indole-3-propionate), which show a modest but statistically significant correlation with lifetime total duration of breastfeeding. The metabolite-based breastfeeding score significantly inversely associate with T2D incidence (HR = 0.76, 95%CI = 0.71-0.82) and with CVD incidence (HR = 0.88, 95%CI = 0.84-0.93) independent of T2D and CVD risk factors. We identify plasma metabolite profiles in mid-life associated with breastfeeding duration, which is also linked to CVD and T2D risk.

> **中文摘要：**
> 前瞻性研究表明，母乳喂养与心脏代谢疾病的发生率呈负相关；然而，这种关联背后的代谢途径仍 largely 未明。本研究利用护士健康研究队列（n = 4349）中的弹性网正则回归方法，基于终生总哺乳时间推导出血浆代谢组评分，并在女性健康倡议队列（n = 2088）中进行了重复验证。数据包括在中年采集的血液样本中，通过液相色谱-质谱技术获得的181种非靶向血浆代谢物，以及受试者自报的终生总哺乳时间。随后，我们利用多变量Cox回归模型考察基于代谢物的哺乳评分与2型糖尿病（T2D）和心血管疾病（CVD）风险之间的关系，并在两个外部队列中进行了重复验证。该基于代谢物的哺乳评分由5种代谢物组成（即C54:2三酰甘油、C56:2三酰甘油、C56:3三酰甘油、可替宁、吲哚-3-丙酸），其与终生总哺乳时间存在中等但具有统计学意义的相关性。该评分与T2D发病率显著负相关（HR = 0.76，95% CI = 0.71-0.82），且与CVD发病率同样呈显著负相关（HR = 0.88，95% CI = 0.84-0.93），这一关联独立于传统的T2D与CVD风险因素。我们识别出中年期血浆代谢物特征与哺乳持续时间相关，该特征亦与CVD和T2D风险相关。

### 第二部分 AI 大师评价

本研究旨在阐明母乳喂养与心脏代谢疾病之间关系的潜在代谢机制。研究者利用大型前瞻性女性队列及血浆代谢组学数据，构建了一个基于代谢物的哺乳时间评分，并在独立人群中进行了重复验证。结果显示，该评分与2型糖尿病及心血管疾病风险均呈显著负相关，提示哺乳可能通过特定代谢通路带来长期代谢获益。其创新之处在于结合机器学习与代谢组学方法揭示生理行为与代谢健康的联系，但研究仍受限于自报哺乳时间及观察性设计。

---

## 27. 岩藻糖基转移酶在健康与疾病中的结构、功能及其意义

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360793)
**期刊：** Nature communications
**PMID：** 41360793
**DOI：** 10.1038/s41467-025-66871-w

### 第一部分 原文与翻译

**英文原标题：** Structure, function, and implications of fucosyltransferases in health and disease.

> **英文摘要：**
> Fucosylation is a ubiquitous glycosylation event that shapes cellular communication and immunity. Catalyzed by fucosyltransferases (FUTs), this reaction encompasses diverse substrates, mechanisms, and biologic consequences. In this Review, we explore the structural and functional landscape of FUTs primarily from higher eukaryotes, with focus on the mechanistic determinants of regioselectivity, donor/acceptor coordination, and domain modularity. We highlight advances in structural biology, modeling, and enzyme engineering that clarify how FUTs decode glycan topology and specificity. Phylogenetic and structural analyses reveal two major clades of human FUTs that differ in GDP-Fuc recognition and conformational flexibility, providing a molecular rationale for their mechanistic divergence. Drawing from mammalian FUT studies, we propose a conceptual framework in which distinct family members exploit strategies including donor-induced conformational changes, exosite interactions, or local peptide cues to achieve specificity and catalytic efficiency. We also examine their roles in physiology, inflammation, immune regulation, and cancer, and summarize current FUT inhibitors and enzyme-based therapeutic strategies.

> **中文摘要：**
> 岩藻糖基化是一种普遍存在的糖基化事件，塑造了细胞间通信与免疫反应。该反应由岩藻糖基转移酶（FUTs）催化，涵盖多种底物、机制及生物学后果。在本综述中，我们主要探讨高等真核生物中FUTs的结构和功能图景，重点关注其区域选择性、供体/受体配合及结构域模块化的机制决定因素。我们强调了结构生物学、建模及酶工程方面的最新进展，这些进展揭示了FUTs如何解读糖链拓扑结构与特异性的分子基础。系统发育与结构分析显示，人类FUTs可分为两个主要分支，它们在GDP-岩藻糖识别及构象柔性上存在差异，从而为其机制分化提供了分子层面的解释。基于哺乳动物FUT的研究，我们提出了一个概念框架，认为不同家族成员可通过供体诱导的构象变化、外位点相互作用或局部肽段信号等策略来实现特异性与催化效率。我们还探讨了其在生理、炎症、免疫调控及癌症中的作用，并总结了当前FUT抑制剂及基于酶的治疗策略。

### 第二部分 AI 大师评价

本综述系统梳理了岩藻糖基转移酶（FUTs）的结构与功能特征，揭示其在糖链识别、区域特异性及酶催化机制方面的多样性。作者结合结构生物学与系统发育分析，提出了FUT家族机制分化的分子基础，并归纳了其在免疫调控与肿瘤发生中的重要作用。文章创新性地构建了一个解释FUT特异性与催化效率的概念框架，有助于指导未来药物和酶工程研究。其局限在于对低等生物或非典型FUT亚型的研究覆盖仍相对不足。

---

## 28. 克隆性细胞状态将胃食管交界组织与化生和癌症相联系。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360789)
**期刊：** Nature communications
**PMID：** 41360789
**DOI：** 10.1038/s41467-025-66302-w

### 第一部分 原文与翻译

**英文原标题：** Clonal cell states link gastroesophageal junction tissues with metaplasia and cancer.

> **英文摘要：**
> Barrett's esophagus is a common type of metaplasia and a precursor of esophageal adenocarcinoma. However, the cell states and lineage connections underlying the origin, maintenance, and progression of Barrett's esophagus have not been resolved in humans. Here, we perform single-cell lineage tracing and transcriptional profiling of patient cells isolated from metaplastic and healthy tissue. Our analysis unexpectedly reveals evidence for lineages spanning squamous esophagus, gastric cardia, and transitional basal cells at the tissue junction. We also identify lineages connecting Barrett's esophagus to both esophageal and gastric tissues. Barrett's esophagus biopsies consist of multiple distinct clones, with lineages that contain all progenitor and differentiated cell types. We discover Barrett's esophagus cell types, including tuft, ciliated, and BEST4+ cells, which we validate through both lineage relationships and spatial transcriptomics. In contrast, the precancerous dysplastic lesions show expansion from a single molecularly aberrant Barrett's esophagus clone. Together, these findings provide a single-cell view of the cell dynamics of Barrett's esophagus, linking cell states along the disease trajectory, from its origin to cancer.

> **中文摘要：**
> 巴雷特食管是一种常见的化生类型，也是食管腺癌的前驱病变。然而，巴雷特食管的起源、维持和进展所涉及的细胞状态及谱系联系在人类中尚未得到解析。在本研究中，我们对来自化生组织和健康组织的患者细胞进行了单细胞谱系追踪和转录组分析。我们的分析意外地揭示了跨越鳞状食管、胃贲门和组织交界处过渡基底细胞的谱系证据。我们还识别出连接巴雷特食管与食管和胃组织的谱系。巴雷特食管活检样本由多个不同的克隆组成，这些谱系包含所有祖细胞和分化细胞类型。我们发现了巴雷特食管中的特定细胞类型，包括tuft细胞、纤毛细胞和BEST4+细胞，并通过谱系关系和空间转录组学验证了这些发现。相比之下，癌前的不典型增生病变表现为源自单一分子异常巴雷特食管克隆的扩增。总体而言，这些发现从单细胞层面揭示了巴雷特食管的细胞动力学，连接了从起源到癌变的疾病演进过程中不同的细胞状态。

### 第二部分 AI 大师评价

本研究以单细胞谱系追踪与转录组分析为核心，系统揭示了巴雷特食管起源与进展过程中的细胞状态及谱系关系。作者发现胃食管交界处存在跨组织谱系，并识别出多种特异性细胞类型，深化了对化生病变组织多克隆特征的理解。研究的创新在于以单细胞水平解析疾病演化的连续性，为阐明从正常组织到癌变的细胞动力学提供了新视角。然而，研究样本量及功能验证的局限仍需在后续工作中进一步完善。

---

## 29. 核小体解卷与PARP1变构调控共同驱动其对染色质和DNA断裂的结合亲和力。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360787)
**期刊：** Nature communications
**PMID：** 41360787
**DOI：** 10.1038/s41467-025-67071-2

### 第一部分 原文与翻译

**英文原标题：** Nucleosome unwrapping and PARP1 allostery drive affinities for chromatin and DNA breaks.

> **英文摘要：**
> Poly(ADP-ribose) polymerase 1 (PARP1) detects DNA strand breaks that occur in duplex DNA and chromatin. Here, correlative optical tweezers and fluorescence microscopy reveal how single molecules of PARP1 identify single-strand breaks (i.e., nicks), undamaged nucleosome core particles (NCP) and NCPs containing DNA nicks. Fluorescently-tagged PARP1 or PARP2 from nuclear extracts binds nicks with nanomolar affinity but does not engage undamaged dsDNA regions. In contrast, PARP1 avidly binds undamaged NCPs, and partial NCP unwrapping induced by DNA tension significantly increases PARP1 on rate and affinity. Catalytically dead PARP1 or EB-47 inhibition greatly increases PARP1 affinity to DNA nicks and undamaged NCP, implicating a mechanism where PARP1 reverse allostery regulates PARP1 retention to undamaged chromatin. We also monitor ADP-ribosylation in real time upon PARP1 binding undamaged or nicked NCPs. These results provide key mechanistic insights into domain allostery and how pharmacological intervention alters PARP1 binding dynamics for therapeutic impacts.

> **中文摘要：**
> 多聚(ADP-核糖)聚合酶1（PARP1）能够检测发生在双链DNA和染色质中的DNA链断裂。本文利用相关性光镊与荧光显微技术揭示了单分子PARP1如何识别单链断裂（即DNA切口）、未受损的核小体核心颗粒（NCP）及含切口的NCP。从细胞核提取物中获得的荧光标记PARP1或PARP2能以纳摩尔级亲和力结合DNA切口，但不会与未受损的双链DNA区域相互作用。相比之下，PARP1能强烈结合未受损NCP，而由DNA张力诱导的NCP部分解卷显著提升PARP1的结合速率与亲和力。催化失活的PARP1或EB‑47抑制剂可大幅增强PARP1对DNA切口及未受损NCP的亲和力，提示一种机制：PARP1的反向变构调控其在未受损染色质上的停留。研究者还实时监测了PARP1结合未受损或含切口NCP时的ADP‑核糖化过程。这些结果为理解PARP1结构域的变构机制及药理干预如何改变其结合动力学提供了关键的分子机制洞见。

### 第二部分 AI 大师评价

本研究通过结合光镊与荧光显微技术，在单分子层面揭示了PARP1识别DNA断裂和核小体状态的机制。作者发现核小体解卷与PARP1变构调控共同决定其对染色质和DNA切口的结合亲和力。催化失活或药物抑制显著改变PARP1的结合动力学，揭示了PARP1反向变构在染色质维持中的作用。研究在安全药物干预和DNA修复机制理解方面具有重要创新性，但仍需进一步探讨其在细胞和体内环境中的动态调控。

---

## 30. ARID1A缺失诱导的MAP4磷酸化使结直肠癌细胞对EMP更加敏感

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360780)
**期刊：** Cell death & disease
**PMID：** 41360780
**DOI：** 10.1038/s41419-025-08286-5

### 第一部分 原文与翻译

**英文原标题：** MAP4 phosphorylation induced by ARID1A loss sensitizes colorectal cancer cells to EMP.

> **英文摘要：**
> Mutational inactivation of the tumor suppressor gene ARID1A is a key driver of tumorigenesis in various types of cancer, making it a promising therapeutic target for anticancer drug development. Here, we performed a synthetic lethal drug screening in an approved drug library with ARID1A isogenic CRC cell lines and identified estramustine phosphate sodium (EMP), an FDA approved antimicrotubule chemotherapy drug, as a synthetic lethal partner of ARID1A. ARID1A loss increases the vulnerability to EMP. Mechanistically, ARID1A loss increases the phosphorylation level of MAP4 (microtubule-associated protein 4), which is a key microtubule dynamics regulator in cancer cells. Therefore, ARID1A loss attenuates microtubule stabilizing activity of MAP4 and creates a dependence on its residual activity. By targeting MAP4, EMP severely disrupts microtubule dynamics, affecting bipolar spindle formation and positioning, and inducing mitotic cell death in ARID1A-deficient cells. Furthermore, we identified that MAP4 is phosphorylated by PI3K, which is activated by ARID1A loss. These findings highlight MAP4 as a key regulator of microtubule dynamics in ARID1A-deficient cells and unveil a novel synthetic lethality relationship between ARID1A and EMP.

> **中文摘要：**
> 肿瘤抑制基因ARID1A的突变性失活是多种癌症发生的关键驱动因素，使其成为抗癌药物研发中潜在的治疗靶点。在本研究中，我们在ARID1A同基因型结直肠癌（CRC）细胞系中，利用已批准药物库进行了合成致死性药物筛选，并鉴定出经FDA批准的抗微管化疗药物磷酸雌莫司汀钠（EMP）是ARID1A的合成致死性伴侣。ARID1A缺失会增加细胞对EMP的易感性。在机制上，ARID1A的缺失会提高MAP4（微管相关蛋白4）的磷酸化水平，而MAP4是癌细胞中调控微管动态变化的关键调节因子。因此，ARID1A的缺失削弱了MAP4的微管稳定作用，并使细胞依赖其剩余活性。通过靶向MAP4，EMP会严重破坏微管动态，影响双极纺锤体的形成与定位，并在ARID1A缺乏的细胞中诱导有丝分裂性细胞死亡。此外，我们发现MAP4的磷酸化由PI3K介导，而PI3K的活化由ARID1A缺失引发。这些发现强调了MAP4在ARID1A缺陷细胞中作为微管动态关键调节因子的作用，并揭示了ARID1A与EMP之间一种新的合成致死性关系。

### 第二部分 AI 大师评价

该研究聚焦于ARID1A缺失在结直肠癌细胞中引发的分子改变，并通过合成致死性筛选发现了EMP作为潜在治疗药物。研究揭示ARID1A缺失可促进MAP4的PI3K依赖性磷酸化，从而影响微管稳态与细胞有丝分裂过程。该工作创新性在于揭示了ARID1A与微管动力学的分子联系，并提出EMP对ARID1A缺陷癌细胞的特异性杀伤作用。然而，仍需进一步的体内验证和临床转化研究以评估其应用潜力。

---

## 31. 靶向依赖CDK9的转录成瘾：通过腺苷脱氨酶调节实现的口腔癌发生新型化学预防策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360777)
**期刊：** Cell death & disease
**PMID：** 41360777
**DOI：** 10.1038/s41419-025-08224-5

### 第一部分 原文与翻译

**英文原标题：** Targeting CDK9-dependent transcriptional addiction: a novel chemoprevention strategy for oral carcinogenesis via adenosine deaminase modulation.

> **英文摘要：**
> Oncogenic dysregulation of transcription can entail defective control of gene expression and drive tumor initiation. This addiction to certain transcriptional programs provides opportunities to prevent carcinogenesis, and targeting transcriptional cyclin-dependent kinases (tCDKs) holds promise to show clinical benefit. Here, we firstly reported that transcriptional addiction existed in the process of oral mucosal carcinogenesis and high expression of CDK9 contributed to transcriptional dysregulation. CDK9 inhibition paused RNA Pol II transcription cycle to induce cell apoptosis in vitro and in vivo, effectively hampering carcinogenesis in 4-NQO-induced mouse models. Mechanically, targeting CDK9 decreased adenosine deaminase (ADA) expression and suppressed ADA activity, impacting on the enzymatic conversion of adenosine to inosine and resultantly caused cell apoptosis. Our findings indicate the important roles of the CDK9-dependent transcriptional addiction in precancerous stage of oral mucosal carcinogenesis, and come up with novel strategy to prevent malignant transformation of precancerous diseases. Model diagram for the role of CDK9-dependent transcriptional addiction in oral carcinogenesis. Transcriptional addiction is an important feature in the process of oral mucosal carcinogenesis. Targeting this CDK9-dependent transcriptional addiction induces cell apoptosis by downregulating ADA, and thereby interfering the enzymatic conversion of adenosine to inosine to hamper oral mucosal carcinogenesis.

> **中文摘要：**
> 致癌性转录失调可能导致基因表达控制缺陷并推动肿瘤的起始。这种对特定转录程序的“成瘾”特征为预防癌变提供了机会，而靶向转录周期蛋白依赖性激酶（tCDKs）有望带来临床获益。在本研究中，我们首次报道了转录成瘾存在于口腔黏膜癌变过程中，并发现CDK9的高表达促进了转录失调。抑制CDK9可使RNA聚合酶II的转录循环停滞，从而在体内外诱导细胞凋亡，并有效阻止4-NQO诱导的小鼠口腔癌发生机制。机制上，靶向CDK9可降低腺苷脱氨酶（ADA）的表达并抑制ADA活性，从而影响腺苷向次黄嘌呤核苷的酶促转化，最终导致细胞凋亡。我们的研究结果表明，依赖CDK9的转录成瘾在口腔黏膜癌变的癌前阶段中具有重要作用，并提出了一种预防癌前疾病恶变的新策略。文中模型图示展示了CDK9依赖转录成瘾在口腔癌发生中的作用。转录成瘾是口腔黏膜癌变过程中的重要特征。靶向这种依赖CDK9的转录成瘾可通过下调ADA诱导细胞凋亡，从而干扰腺苷向次黄嘌呤核苷的酶促转化过程，抑制口腔黏膜癌变。

### 第二部分 AI 大师评价

该研究揭示了CDK9依赖的转录成瘾在口腔黏膜癌变过程中的关键作用，并通过腺苷脱氨酶调控阐明了其分子机制。作者采用体内外实验及动物模型，验证了CDK9抑制可阻断致癌进程、诱导细胞凋亡，为癌前病变化学预防提供了新思路。研究创新性体现在将转录依赖性成瘾与代谢酶活性联系起来，提出了靶向CDK9的疾病预防潜力。局限性在于尚需临床验证其安全性与长期效应。

---

## 32. 基于皮肤镜检查的黑色素瘤转移预测模型：一项国际多中心回顾性人工评估研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360775)
**期刊：** Nature communications
**PMID：** 41360775
**DOI：** 10.1038/s41467-025-65972-w

### 第一部分 原文与翻译

**英文原标题：** Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study.

> **英文摘要：**
> Current melanoma prognostic tools have limited clinical use at the bedside, highlighting the need for more effective biomarkers. Dermatoscopy correlates with established prognostic markers obtained through invasive procedures. However, its direct predictive value for metastasis remains unexplored. In this multinational study, 30 dermatologists evaluated 776 dermatoscopic images of melanomas (stage IB and above) for predefined criteria including structures, colors and vessels. Extensive dermatoscopic ulceration and blue-white veil are associated with increased risk of metastasis in the total cohort and reduced recurrence-free survival in early-stage melanomas, while extensive regression is associated with reduced metastasis risk and improved recurrence-free survival. Three predictive models of metastasis: (1) dermatoscopic features only, (2) histopathologic features only, and (3) a combination of both demonstrate comparable prognostic accuracy. Here, we show that dermatoscopy may offer valuable prognostic insights into melanoma's biological behavior before excision and help guide therapeutic decisions. Prospective validation in future trials is essential.

> **中文摘要：**
> 目前黑色素瘤的预后评估工具在临床床旁的实际应用有限，凸显了对更有效生物标志物的需求。皮肤镜检查与通过侵入性操作获得的既有预后标志物存在相关性。然而，其对转移的直接预测价值仍未得到探索。在这项多国研究中，30名皮肤科医生对776张黑色素瘤（IB期及以上）皮肤镜图像进行了评估，依据预设标准分析结构、颜色和血管特征。结果显示，广泛的皮肤镜下溃疡及蓝白面纱与总体队列中较高的转移风险以及早期黑色素瘤中较短的无复发生存期相关；而广泛的退行性改变与较低的转移风险及较长的无复发生存期相关。研究建立了三种转移预测模型：（1）仅基于皮肤镜特征，（2）仅基于组织病理特征，以及（3）结合皮肤镜与组织病理特征，三者具有相当的预后准确性。本研究表明，皮肤镜检查可在切除前为黑色素瘤的生物学行为提供有价值的预后洞见，有助于指导治疗决策。未来仍需通过前瞻性试验进行验证。

### 第二部分 AI 大师评价

该研究旨在探索皮肤镜检查在黑色素瘤转移风险预测中的潜在价值，基于多国回顾性图像分析，构建并比较了三种预测模型。结果揭示了特定皮肤镜特征（如蓝白面纱、广泛溃疡、退行性改变）与转移风险及无复发生存期的显著相关性。研究创新性地提出皮肤镜观察可作为非侵入性预后评估手段，为手术前风险分层提供支持。其局限在于研究为回顾性设计，尚需前瞻性临床验证以确认模型的普适性与临床实用性。

---

## 33. 癌症中的中性粒细胞胞外诱捕网：免疫调节、治疗耐受及靶向困境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360771)
**期刊：** Cell death & disease
**PMID：** 41360771
**DOI：** 10.1038/s41419-025-08218-3

### 第一部分 原文与翻译

**英文原标题：** Neutrophil extracellular traps in cancer: immune modulation, therapy resistance, and the dilemma of targeting.

> **英文摘要：**
> The release of extracellular DNA is a highly conserved mechanism across species. Extracellular traps released by neutrophils (NETs) represent a strategic defensive tool of the organism against pathogens, through their direct entrapment and killing, but also through the immunoadjuvant ability of their components. In this review, we discuss the involvement of NETs in cancer, from tumour initiation to recurrence, touching also on their role in cancer-associated comorbidities. We also discuss the emerging contribution of NETs in resistance to chemotherapy, radiotherapy and, particularly, immunotherapy, because of their suppression of cytotoxic immune responses and remodelling of the tumour microenvironment into an immune-tolerant niche. The therapeutic dilemma lies in whether targeting NETs to restore anti-tumour immunity may compromise the host's defence against infections, an adverse effect that is far from negligible in patients who are often already immunocompromised. Furthermore, despite their widely recognized pro-tumoral functions, NETs have also been implicated in supporting anti-tumour immunity in specific contexts. The key challenge, therefore, lies in distinguishing between "bad" pro-tumoral NETs and "good" anti-microbial/anti-tumoral NETs, both for identifying reliable biomarkers and for developing more precise NET-based therapeutic targets.

> **中文摘要：**
> 胞外 DNA 的释放是一种跨物种高度保守的机制。由中性粒细胞释放的胞外诱捕网（NETs）代表机体对抗病原体的一种战略性防御工具，不仅通过其直接捕获和杀灭作用，还通过其组分的免疫佐剂功能发挥作用。在本综述中，我们讨论了 NETs 在癌症中的参与过程，从肿瘤的起始到复发，并涉及其在癌症相关合并症中的作用。我们还探讨了 NETs 在化疗、放疗，尤其是免疫治疗耐受中的新兴作用，这主要归因于其抑制细胞毒性免疫反应及将肿瘤微环境重塑为免疫耐受性生态位。治疗上的困境在于，靶向 NETs 以恢复抗肿瘤免疫是否可能损害宿主对感染的防御，这种不良后果在患者通常已处于免疫抑制状态时绝不可忽视。此外，尽管 NETs 的促肿瘤功能已被广泛认可，但已有研究显示其在特定情境下也可能支持抗肿瘤免疫。因此，关键挑战在于区分“有害”的促肿瘤型 NETs 与“有益”的抗菌/抗肿瘤型 NETs，这对于识别可靠生物标志物及开发更精确的 NETs 靶向治疗手段至关重要。

### 第二部分 AI 大师评价

本文综述了中性粒细胞胞外诱捕网（NETs）在癌症发生、进展及复发中的多重作用，系统探讨其在免疫调节和抗肿瘤治疗耐受中的贡献。作者指出 NETs 通过抑制细胞毒性免疫反应及重塑肿瘤微环境，促进免疫逃逸，并提出靶向 NETs 的治疗策略存在感染风险这一临床难题。文章的创新性在于揭示 NETs 既具促肿瘤又具抗肿瘤潜能的双刃特性，强调区分不同功能 NETs 对于精准治疗的重要意义。本文为发展基于 NETs 的生物标志物和治疗靶点提供了新的思路，但仍需实验与临床层面的证据予以验证。

---

## 34. Smad3信号下调损害结直肠癌中单核样髓源抑制性细胞（MO-MDSC）的成熟。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360769)
**期刊：** Cell death & disease
**PMID：** 41360769
**DOI：** 10.1038/s41419-025-08228-1

### 第一部分 原文与翻译

**英文原标题：** Downregulated Smad3 signaling impairs the maturation of MO-MDSC in colorectal cancer.

> **英文摘要：**
> Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immunosuppressive cells that expand in tumors due to impaired differentiation into macrophages (MΦ), dendritic cells (DC), or granulocytes. Despite extensive research, the mechanisms governing their differentiation remain incompletely understood. Transforming growth factor β1 (Tgfβ1), abundant in the tumor microenvironment (TME), regulates cellular differentiation via the classical Smad2/3 pathway, yet paradoxically fails to drive MDSC maturation. In this study, we demonstrate that Smad3 is significantly downregulated in MDSC from colorectal cancer (CRC) patients and tumor-bearing mouse models, impairing monocytic lineage maturation. Myeloid-specific Smad3 overexpression promotes the differentiation of MO-MDSC into mature MΦ and DC, enhances MHC-II expression, and reduces immunosuppressive molecules, thereby attenuating tumor progression. Mechanistically, Tgfβ1 induces MO-MDSC expansion via the non-classical PI3K/AKT pathway, which is counteracted by Smad3 overexpression. Furthermore, Mettl3-mediated mA modification destabilizes Smad3 mRNA at the 3'UTR, linking RNA epigenetics to MDSC dysfunction. Clinically, plasma Tgfβ1 levels correlate with the MO-MDSC/PMN-MDSC ratio across cancer types, highlighting its biomarker potential. Our findings unveil Smad3 as a critical regulator of MDSC fate and propose novel therapeutic targets for tumor immunotherapy.

> **中文摘要：**
> 髓源性抑制性细胞（MDSC）是一类异质性的免疫抑制细胞群体，由于其向巨噬细胞（MΦ）、树突状细胞（DC）或粒细胞的分化受阻而在肿瘤中扩增。尽管已有广泛研究，但调控其分化的机制仍未完全阐明。肿瘤微环境（TME）中丰富的转化生长因子β1（Tgfβ1）通过经典的Smad2/3通路调控细胞分化，但矛盾的是，它未能推动MDSC的成熟。在本研究中，我们发现结直肠癌（CRC）患者及肿瘤负荷小鼠模型中的MDSC中Smad3显著下调，从而削弱了单核系的成熟。髓系特异性Smad3过表达可促进MO-MDSC分化为成熟的MΦ和DC，增强MHC-II表达，降低免疫抑制分子，从而减缓肿瘤进展。从机制上看，Tgfβ1通过非经典的PI3K/AKT通路诱导MO-MDSC扩增，而这一过程可被Smad3过表达抵消。此外，Mettl3介导的mA修饰可在Smad3 mRNA的3'UTR位置降低其稳定性，从而将RNA表观遗传学与MDSC功能障碍联系起来。在临床上，不同癌种中血浆Tgfβ1水平与MO-MDSC/PMN-MDSC比例相关，提示其作为生物标志物的潜力。我们的发现揭示了Smad3作为MDSC命运关键调控因子的作用，并提出了新的肿瘤免疫治疗靶点。

### 第二部分 AI 大师评价

本研究揭示了结直肠癌中Smad3信号下调导致MO-MDSC成熟受损的关键机制。研究通过患者样本与肿瘤小鼠模型相结合，阐明了Tgfβ1–Smad3轴及PI3K/AKT非经典通路在MDSC分化中的对抗性作用，并指出Mettl3介导的RNA修饰在其中的调节作用。该研究创新性地建立了Smad3与MDSC命运的分子联系，为肿瘤免疫治疗提供了潜在新靶点。其局限性在于机制验证仍需更多临床功能性实验支撑。

---

## 35. IL7R 通过调控 NF-κB/CXCL1 轴在卵巢癌中重塑免疫抑制性肿瘤微环境并促进巨噬细胞极化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360767)
**期刊：** Cell death & disease
**PMID：** 41360767
**DOI：** 10.1038/s41419-025-08312-6

### 第一部分 原文与翻译

**英文原标题：** IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-κB/CXCL1 axis in ovarian cancer.

> **英文摘要：**
> In the ovarian cancer microenvironment, the polarization of tumor-associated macrophages (TAMs) is closely associated with immunosuppressive phenotypes. Although elevated levels of circulating interleukin-7 (IL-7) have been linked to a poor prognosis, the regulatory mechanisms underlying this association remain incompletely understood. This study demonstrated that increased IL7R expression in ovarian cancer is correlated with the polarization of CD206 macrophages, the remodeling of the immunosuppressive microenvironment, and unfavorable patient prognosis. By employing 3D bioprinted co-culture systems and mouse models, we showed that the knockdown or knockout of IL7R inhibits tumor progression and intraperitoneal dissemination. Mechanistically, IL7R signaling promotes the polarization of macrophages toward an immunosuppressive phenotype through the NF-κB/CXCL1 axis. This is supported by the upregulated expression of Arg1 and IL-10, as well as the downregulated expression of pro-inflammatory markers. These polarized macrophages further enhance tumor cell proliferation and invasion, thereby forming a tumor-immune feedback loop. In conclusion, this study clarifies how IL7R signaling mediates crosstalk between ovarian cancer cells and macrophages to maintain the homeostasis of the immunosuppressive tumor microenvironment (TME).

> **中文摘要：**
> 在卵巢癌的肿瘤微环境中，肿瘤相关巨噬细胞（TAMs）的极化与免疫抑制性表型密切相关。尽管循环中白细胞介素-7（IL-7）水平升高与不良预后有关，但其背后的调控机制尚未完全阐明。本研究表明，卵巢癌中 IL7R 表达的升高与 CD206 型巨噬细胞的极化、免疫抑制性微环境的重塑以及患者的不良预后密切相关。通过采用三维生物打印共培养系统和小鼠模型，我们发现敲低或敲除 IL7R 能抑制肿瘤进展和腹腔转移。从机制上看，IL7R 信号通过 NF-κB/CXCL1 轴促进巨噬细胞向免疫抑制性表型极化。这一过程伴随着 Arg1 和 IL-10 表达上调以及促炎标志物表达下调。这些极化的巨噬细胞进一步增强肿瘤细胞的增殖和侵袭，从而形成肿瘤—免疫的反馈回路。综上所述，本研究阐明了 IL7R 信号如何介导卵巢癌细胞与巨噬细胞之间的相互作用，以维持免疫抑制性肿瘤微环境（TME）的稳态。

### 第二部分 AI 大师评价

该研究揭示了 IL7R 在卵巢癌中促进巨噬细胞向免疫抑制型极化并重塑肿瘤微环境的关键机制。作者通过 3D 生物打印共培养和小鼠模型结合，系统验证了 IL7R/NF-κB/CXCL1 轴对肿瘤进展的驱动作用。结果阐明 IL7R 可通过上调 Arg1 和 IL-10 表达促进免疫耐受，并形成肿瘤-免疫反馈环路。研究具有重要创新性，为靶向 IL7R 调控肿瘤免疫微环境提供了新思路，但仍需进一步验证其临床转化潜力及特异性。

---

## 36. Mammo-AGE：基于深度学习的乳腺影像生理年龄估计

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360762)
**期刊：** Nature communications
**PMID：** 41360762
**DOI：** 10.1038/s41467-025-65923-5

### 第一部分 原文与翻译

**英文原标题：** Mammo-AGE: deep learning estimation of breast age from mammograms.

> **英文摘要：**
> Biological age is an important indicator of organ functions and health. Although mammograms are widely used in breast cancer screening, the potential of mammogram-based biological age predictors remains underexplored. Here, we propose a deep learning model to estimate the biological age of the breast using healthy mammograms. The model is developed on three large datasets and externally validated on two additional datasets, encompassing 95,826 mammograms from 44,497 women aged 18 to 98 years. It demonstrates accurate age estimation (mean absolute error: 4.2 - 6.1 years) with strong correlation to chronological age. Predicted breast age stratifies breast cancer risk similarly to chronological age. Occlusion analysis, employed for model interpretation, reveals the aging-related pattern of the breast. The breast age gap (the difference between system-bias-corrected breast age and chronological age) may reflect breast health status. Breast cancer patients show higher breast age gaps than the healthy population. In two longitudinal datasets, larger breast age gaps are associated with increased future breast cancer risk, with hazard ratios of 1.013 - 1.022. Furthermore, we finetune the model specifically for downstream breast cancer diagnosis and risk prediction. Our approach outperforms other comparative methods, showing its potential for supporting both early detection and personalized screening strategies.

> **中文摘要：**
> 生物学年龄是评估器官功能和健康状况的重要指标。尽管乳腺X线摄影（乳腺钼靶）在乳腺癌筛查中被广泛应用，但基于乳腺影像的生物学年龄预测潜力尚未得到充分探索。本研究提出一种深度学习模型，用于利用健康乳腺的影像资料估算乳腺的生物学年龄。该模型基于三个大型数据集开发，并在两个额外的外部数据集上进行验证，涵盖来自年龄18至98岁的44,497名女性的95,826张乳腺影像。模型表现出较高的年龄预测精度（平均绝对误差为4.2–6.1岁），并与实际年龄具有高度相关性。预测得到的乳腺年龄可类似于实际年龄对乳腺癌风险进行分层分析。通过用于模型解释的遮挡分析，揭示了乳腺的衰老相关模式。乳腺年龄差（经系统偏倚校正的乳腺年龄与实际年龄之间的差值）可能反映乳腺健康状态。乳腺癌患者的乳腺年龄差高于健康人群。在两个纵向数据集中，较大的乳腺年龄差与更高的未来乳腺癌风险相关，其风险比为1.013–1.022。此外，研究者针对下游的乳腺癌诊断与风险预测对模型进行了微调。该方法优于其他对比模型，显示出在早期检测和个体化筛查策略中的应用潜力。

### 第二部分 AI 大师评价

该研究提出一种创新的深度学习模型，可从健康乳腺影像中估计乳腺的生物学年龄，并通过多中心数据进行验证，预测精度高。研究发现乳腺年龄差与乳腺癌风险显著相关，提示该指标可作为潜在的健康与风险评估工具。模型解释性分析揭示乳腺衰老的影像学模式，丰富了对乳腺生理老化的理解。其创新性在于将人工智能与影像生物学融合，用于个体化健康预测，但模型的可解释性与临床应用推广仍需进一步验证。

---

## 37. LncPEDS1-AS通过DDX23调控PEDS1表达，促进上尿路尿路上皮癌对脂质过氧化的耐受性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360761)
**期刊：** Cell death & disease
**PMID：** 41360761
**DOI：** 10.1038/s41419-025-08293-6

### 第一部分 原文与翻译

**英文原标题：** LncPEDS1-AS promotes UTUC resistance to lipid peroxidation by regulating PEDS1 expression via DDX23.

> **英文摘要：**
> Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a significantly poorer prognosis than bladder cancer (BC). One distinguishing feature of UTUC is its enhanced resistance to reactive oxygen species (ROS)-induced lipid peroxidation, a phenomenon closely associated with adverse clinical outcomes. However, the molecular mechanisms underlying this resistance remain largely unexplored. In this study, we identify LncPEDS1-AS, an ultra-long (>6900 nt) antisense lncRNA, as a key regulator of ROS resistance in UTUC. Mechanistically, LncPEDS1-AS interacts with the splicing factor DDX23, forming a nuclear RNA-protein complex that facilitates the splicing and maturation of PEDS1 pre-mRNA. PEDS1 encodes plasmanylethanolamine desaturase, which plays a protective role against lipid peroxidation. Based on these findings, we developed an antisense oligonucleotide (ASO) therapy strategy targeting LncPEDS1-AS, which effectively suppressed tumour growth and enhanced tumour cells' ROS sensitivity both in vitro and in vivo. Moreover, our findings also highlight the distinctive molecular features and regulatory capacity of ultra-long antisense lncRNAs such as LncPEDS1-AS, which merit further comprehensive exploration in cancer biology.The LncPEDS1-AS-DDX23-PEDS1 axis is involved in resistance to lipid peroxidation and plays a critical role in the prognosis of UTUC (Created with BioRender.com).

> **中文摘要：**
> 上尿路尿路上皮癌（UTUC）是一种罕见的恶性肿瘤，其预后显著差于膀胱癌（BC）。UTUC的一个显著特征是其对活性氧（ROS）诱导的脂质过氧化具有更强的抗性，这种现象与不良临床结局密切相关。然而，该抗性的分子机制仍然在很大程度上未被揭示。在本研究中，我们鉴定出LncPEDS1-AS，这是一种超长（>6900 nt）的反义长链非编码RNA，是UTUC中ROS抗性的关键调控因子。从机制上看，LncPEDS1-AS与剪接因子DDX23相互作用，形成一个核内RNA-蛋白复合物，促进PEDS1前体mRNA的剪接与成熟。PEDS1编码质烷基乙醇胺脱氢酶，该酶在抵御脂质过氧化中发挥保护作用。基于这些发现，我们设计了一种针对LncPEDS1-AS的反义寡核苷酸（ASO）治疗策略，该策略有效抑制了肿瘤生长，并在体内外均增强了肿瘤细胞对ROS的敏感性。此外，我们的研究结果还强调了像LncPEDS1-AS这样的超长反义lncRNA所具有的独特分子特征和调控能力，这值得在癌症生物学中进行更全面的探索。LncPEDS1-AS-DDX23-PEDS1轴参与脂质过氧化的抗性，并在UTUC的预后中发挥关键作用。

### 第二部分 AI 大师评价

本研究聚焦于上尿路尿路上皮癌中脂质过氧化抗性的分子机制，发现超长反义lncRNA——LncPEDS1-AS通过与剪接因子DDX23相互作用，促进PEDS1的成熟表达，从而增强细胞对ROS的耐受性。作者进一步开发了针对LncPEDS1-AS的反义寡核苷酸疗法，有效抑制肿瘤生长并提升ROS敏感性，为UTUC治疗提供了新的分子靶点。研究创新点在于揭示了超长反义lncRNA在剪接调控及抗氧化防御中的独特作用，但其临床转化仍有待长期验证。

---

## 38. 阴离子脂质体作为优化的膜融合载体，实现细胞外囊泡微RNA的原位多重检测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360752)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41360752
**DOI：** 10.1002/advs.202519758

### 第一部分 原文与翻译

**英文原标题：** Anionic Liposomes as Optimal Membrane Fusion Carriers Enabling in Situ Multiplexed Detection of Extracellular Vesicle MicroRNAs.

> **英文摘要：**
> Extracellular vesicle (EV) microRNAs (miRNAs) are promising liquid biopsy biomarkers for non-invasive diagnosis, monitoring, and therapeutic evaluation of cancer. However, sensitive EV miRNA detection is hindered by complex pre-analytical processing. Here, the authors present an anionic liposome (AL) assisted membrane fusion strategy enabling one-step multiplexed quantification of EV miRNAs directly from plasma without EV isolation or RNA extraction, termed EValarm (Anionic Liposome Assisted miRNAs Monitoring for Extracellular Vesicles). Liposomes encapsulating probes are prepared using a microfluidic chip, achieving catalytic signal amplification after target recognition of miRNA. Systematic lipid screening identified ALs as optimal carriers, exhibiting minimal background and superior sensitivity compared to cationic and neutral liposomes. The AL-based assay delivered accuracy comparable to quantitative PCR with a streamlined workflow. Applied to 106 clinical samples from lymphoma patients and healthy controls, integration with artificial intelligence achieved high accuracy (AUC > 0.99). In summary, this study demonstrates a platform enabling direct and sensitive plasma EV miRNA detection, offering strong potential for clinical translation in cancer liquid biopsy.

> **中文摘要：**
> 细胞外囊泡（EV）微RNA（miRNA）是肿瘤非侵入性诊断、监测及治疗评估中具有前景的液体活检生物标志物。然而，EV miRNA 的灵敏检测受到复杂前分析处理步骤的限制。本文作者提出了一种基于阴离子脂质体（AL）辅助膜融合的策略，可在无需分离EV或提取RNA的情况下，直接从血浆中一步实现EV miRNA的多重定量检测，命名为EValarm（Anionic Liposome Assisted miRNAs Monitoring for Extracellular Vesicles）。研究利用微流控芯片制备包载探针的脂质体，并在miRNA靶标识别后实现催化信号放大。系统性脂质筛选结果显示，阴离子脂质体是最优的载体，与阳离子或中性脂质体相比，表现出更低的背景信号和更高的灵敏度。基于AL的检测方法在保持简化操作流程的同时，达到了与定量PCR相当的准确性。该方法应用于106例淋巴瘤患者及健康对照的临床样本中，并结合人工智能分析，实现了极高的准确率（AUC > 0.99）。综上，本研究展示了一种可直接、灵敏检测血浆EV miRNA的平台，具有在肿瘤液体活检中良好的临床转化潜力。

### 第二部分 AI 大师评价

该研究旨在解决EV miRNA检测繁琐的前处理问题，通过引入阴离子脂质体辅助膜融合策略，实现血浆样本中miRNA的一步多重检测。研究方法结合微流控制备与信号放大技术，系统筛选出性能最佳的脂质体类型，显著提升检测灵敏度与特异性。实验结果表明，其检测性能接近定量PCR，并在临床样本中表现出卓越准确性。该技术具有流程简化、灵敏度高及良好临床应用前景的创新性，但其在不同癌种与大规模临床验证中的泛化性仍需进一步评估。

---

## 39. rWTC-MBTA 疫苗单独使用或与抗 PD-1 联合应用可诱导针对中枢神经系统及外周 B 细胞淋巴瘤的免疫应答

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360751)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41360751
**DOI：** 10.1002/advs.202511605

### 第一部分 原文与翻译

**英文原标题：** rWTC-MBTA Vaccine, Alone and Enhanced with Anti-PD1, Elicits Immune Responses against CNS and Peripheral B-Cell Lymphoma.

> **英文摘要：**
> Central nervous system (CNS) lymphomas are difficult to treat due to their aggressive nature, limited brain accessibility, and poor response to conventional therapies. This study evaluates the rWTC-MBTA vaccine, alone or with anti-PD1 therapy, in A20 B-cell lymphoma models. The vaccine alone significantly inhibits tumor growth and extends survival in both subcutaneous and intracranial settings by triggering strong innate and adaptive immune responses, including long-term memory. Immune profiling reveals dynamic responses in lymph nodes and tumor-infiltrating lymphocytes over time. Co-culture assays with lymph node or spleen cells from vaccinated mice show enhanced tumor cell killing and increased IFN-γ and TNF-α levels, indicating lymphoma-specific immunity. In the intracranial model, control mice has dense tumor infiltration in the brain, while vaccinated mice exhibit more dispersed tumors with reduced spread to ventricles and meninges. Vaccination also shifts the tumor microenvironment toward a more active antitumor state, marked by increased PD-1⁺ CD8⁺ T cells. Combining the vaccine with anti-PD1 further enhances antitumor effects. These findings demonstrate that rWTC-MBTA induces potent and durable immune responses against CNS and peripheral lymphomas, offering long-term protection and showing synergistic benefit when combined with immune checkpoint blockade.

> **中文摘要：**
> 由于中枢神经系统（CNS）淋巴瘤具有侵袭性、脑组织可达性受限且对常规治疗反应差，因此其治疗极具挑战。本研究在 A20 B 细胞淋巴瘤模型中评估了 rWTC-MBTA 疫苗单独应用或联合抗 PD-1 治疗的效果。结果显示，仅使用该疫苗即可在皮下及颅内模型中显著抑制肿瘤生长并延长生存期，这种效果源于其能激发强大的先天性与获得性免疫应答，包括长期免疫记忆。免疫谱分析显示，淋巴结及肿瘤浸润性淋巴细胞的免疫应答随时间呈动态变化。将接种疫苗小鼠的淋巴结或脾细胞与肿瘤细胞共培养发现，肿瘤细胞杀伤能力明显增强，并伴随 IFN-γ 和 TNF-α 水平升高，提示产生了针对淋巴瘤的特异性免疫反应。在颅内模型中，对照组小鼠脑部出现密集的肿瘤浸润，而接种组小鼠肿瘤更为分散，且向脑室及脑膜的扩散减少。疫苗接种还使肿瘤微环境向更活跃的抗肿瘤状态转变，其特征为 PD-1⁺ CD8⁺ T 细胞的增加。将疫苗与抗 PD-1 联合应用可进一步增强抗肿瘤效应。这些发现表明，rWTC-MBTA 可诱导对中枢及外周淋巴瘤的强效且持久的免疫应答，具有提供长期保护的潜力，并在与免疫检查点阻断联合时展现协同优势。

### 第二部分 AI 大师评价

该研究旨在通过评估 rWTC-MBTA 疫苗单独或联合抗 PD-1 治疗对 CNS 及外周 B 细胞淋巴瘤的免疫效应，探索其潜在的免疫治疗价值。结果显示，疫苗可诱发显著的先天及获得性免疫反应，改善肿瘤微环境并延长生存期。免疫学分析揭示其特异性激活了 CD8⁺ T 细胞及细胞因子释放，形成持久免疫记忆。研究创新性在于验证了疫苗在脑内肿瘤模型中的有效性及与免疫检查点抑制剂的协同作用。局限性可能在于仍需进一步临床前验证及安全性评估。

---

## 40. 基于 H⁺ 交换驱动的 ppb 级超高选择性甲醛室温检测用于环境与临床应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360738)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41360738
**DOI：** 10.1002/advs.202518324

### 第一部分 原文与翻译

**英文原标题：** H⁺ Exchange-Driven ppb-Level and High-Selective Formaldehyde Detection at Room Temperature for Environmental and Clinical Applications.

> **英文摘要：**
> Formaldehyde is both a pervasive air pollutant and a critical breath biomarker for tumor-related diseases, yet its reliable detection remains difficult due to ultralow concentrations and interference from ubiquitous volatile organic compounds (VOCs). Here, an H⁺-exchange strategy is reported that markedly enhances the sensing performance of sodium titanate (NaTiO, NTO) by introducing abundant surface hydroxyl groups and tuning conduction pathways. In H⁺-exchanged NTO (H-NTO), hydroxyl groups act as selective adsorption sites for formaldehyde, while formaldehyde adsorption simultaneously suppresses surface-proton and internal-electron conduction by increasing the activation energy for proton hopping and generating electron-trapping states. This dual modulation effectively eliminates cross-sensitivity to other VOCs (e.g., methanol), enabling H-NTO to achieve an ultralow detection limit of 2 ppb, a wide dynamic range up to 100 ppm, and stable operation over two months-contrasting with the negligible response of pristine NTO. To demonstrate practical utility, we developed a handheld H-NTO prototype for wireless indoor air-quality monitoring and non-invasive breath-based breast cancer screening. Coupled with machine learning, the system achieved high diagnostic accuracy, establishing H⁺-exchange as a powerful route toward next-generation intelligent formaldehyde sensors.

> **中文摘要：**
> 甲醛既是一种普遍存在的空气污染物，也是肿瘤相关疾病的重要呼气生物标志物，然而由于其极低浓度以及来自普遍存在的挥发性有机化合物（VOCs）的干扰，可靠检测仍然具有挑战性。本研究报道了一种 H⁺ 交换策略，通过引入丰富的表面羟基并调控导电通道，显著提升了钛酸钠（NaTiO，NTO）的传感性能。在 H⁺ 交换后的 NTO（H-NTO）中，羟基作为甲醛的选择性吸附位点，而甲醛的吸附同时通过增加质子跃迁的活化能和产生电子陷阱态，抑制了表面质子和内部电子的传导。这种双重调控有效消除了对其他 VOCs（如甲醇）的交叉敏感性，使 H-NTO 实现了 2 ppb 的超低检测限、最高达 100 ppm 的宽动态范围，并能在两个月内保持稳定运行——与原始 NTO 几乎无响应形成鲜明对比。为了验证其实用性，研究团队开发了一种用于无线室内空气质量监测和无创呼气乳腺癌筛查的手持式 H-NTO 原型装置。结合机器学习，该系统实现了高诊断准确率，确立了 H⁺ 交换作为构建下一代智能甲醛传感器的强大途径。

### 第二部分 AI 大师评价

本研究旨在通过 H⁺ 交换策略显著提高钛酸钠基甲醛传感器的灵敏度与选择性。研究者通过调控材料的表面化学与电导特性，实现了对甲醛的特异性识别，并避免了常见 VOCs 的干扰。在室温条件下，H-NTO 传感器达到了 ppb 级检测限与长周期稳定性，且成功应用于呼气乳腺癌筛查原型设备中。该工作在环境监测与临床呼气分析领域具有重要创新性，但未来仍需评估其长期稳定性及在复杂生物气体中的实际表现。

---

## 41. METTL1介导的mG tRNA修饰通过翻译调控促进肝切除术后残余肝再生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360736)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41360736
**DOI：** 10.1002/advs.202507329

### 第一部分 原文与翻译

**英文原标题：** METTL1-Mediated MG tRNA Modification Promotes Residual Liver Regeneration After Hepatectomy via Translational Control.

> **英文摘要：**
> Partial hepatectomy (PHx) has emerged as a primary therapeutic intervention for end-stage liver pathologies. However, post-hepatectomy liver failure (PHLF), a critical complication arising from inadequate regenerative capacity of the remnant liver, underscores the clinical imperative to understand molecular mechanisms governing hepatic regeneration. Through an integrative multi-omics analysis in a murine 70% PHx model coupled with clinical correlation studies, the tRNA mG methyltransferase METTL1 was identified as a pivotal regulator of post-resection hepatic recovery. METTL1 exhibited significant temporal upregulation following PHx, with its expression profile positively correlating with favorable clinical outcomes in surgical patients. Genetic ablation of METTL1 substantially attenuated hepatocyte proliferation and compromised regenerative capacity, whereas its ectopic expression potentiated liver regeneration through enhanced translational efficiency. Mechanistic investigations revealed that METTL1-mediated mG tRNA modification orchestrates regenerative processes by selectively augmenting the translation of Hippo pathway effectors YAP/TAZ. Most importantly, modulation of the METTL1-YAP/TAZ signaling axis successfully promotes liver regeneration after PHx. This study elucidates a previously unrecognized translational control mechanism underlying liver regeneration, proposing METTL1 as a promising molecular target for preventing PHLF through therapeutic enhancement of hepatic regenerative potential.

> **中文摘要：**
> 部分肝切除术（PHx）已成为终末期肝脏疾病的主要治疗手段。然而，术后肝衰竭（PHLF）是由于残余肝再生能力不足而产生的严重并发症，凸显了深入理解调控肝脏再生分子机制的临床重要性。通过在小鼠70%肝切除模型中结合多组学整合分析和临床相关性研究，研究者发现tRNA mG甲基转移酶METTL1是术后肝脏恢复的关键调节因子。METTL1在PHx后显著且随时间上调，其表达模式与手术患者良好的临床预后呈正相关。METTL1的基因敲除显著削弱了肝细胞增殖并损害了再生能力，而其异位过表达则通过增强翻译效率促进了肝脏再生。机制研究表明，METTL1介导的mG tRNA修饰通过选择性增强Hippo通路效应因子YAP/TAZ的翻译来协调再生过程。更重要的是，对METTL1–YAP/TAZ信号轴的调控成功促进了PHx后的肝再生。本研究揭示了一种先前未被识别的肝脏再生翻译控制机制，并提出METTL1作为预防PHLF、增强肝再生潜能的有前景的分子靶点。

### 第二部分 AI 大师评价

本研究旨在揭示肝部分切除术后再生能力受分子层面调控的机制，采用多组学整合及临床验证策略，发现METTL1通过mG tRNA修饰在肝再生过程中发挥核心作用。研究证明METTL1可通过上调YAP/TAZ转译效率来增强再生能力，提示其在翻译调控网络中的关键地位。该工作创新性地连接了tRNA修饰与Hippo通路调节，拓宽了对肝再生调控的理解。其局限性可能在于动物模型向临床转化的可行性仍需进一步验证。

---

## 42. 乙醇特异性应激与 RAB25/GCN1 信号通路：酒精相关性肝病的新兴视角

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360083)
**期刊：** Clinical and molecular hepatology
**PMID：** 41360083
**DOI：** 10.3350/cmh.2025.1360

### 第一部分 原文与翻译

**英文原标题：** Ethanol‑Specific Stress and RAB25/GCN1 Signaling: Emerging Perspectives in Alcohol‑Associated Liver Disease.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究题目聚焦于乙醇特异性应激反应与 RAB25/GCN1 信号通路在酒精相关性肝病中的作用与机制，体现了对分子层面病理过程的新探索。其理论意义在于揭示酒精诱导肝损伤的细胞应激和信号调控新轴线，为未来靶向治疗提供思路。尽管暂无摘要内容可进一步说明研究设计与结果，但从标题推测，该研究可能结合分子实验与转录组分析手段，系统评估关键信号因子在肝组织损伤中的功能。整体而言，该论文的创新性在于提出了新的信号联结假说，但仍需通过功能验证和临床关联分析进一步支撑。

---

## 43. 接受免疫检查点抑制剂治疗患者的免疫性血小板减少症

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359796)
**期刊：** Blood
**PMID：** 41359796
**DOI：** 10.1182/blood.2025031449

### 第一部分 原文与翻译

**英文原标题：** Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

> **英文摘要：**
> Immune checkpoint inhibitor-associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016-2023 at 29 U.S. hospitals across seven major cancer centers to identify cases of ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86,467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage 4 cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (IQR, 4-18) after ICI initiation, with a median nadir platelet count of 41 x109/L (IQR, 17-64). Patients were treated with glucocorticoids (n=106, [49.5%]), immune globulin (n=39 [18.2%]), and thrombopoietin receptor agonists (n=29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP compared with those without ICI-ITP (adjusted HR 2.96 [95% CI, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.

> **中文摘要：**
> 与免疫检查点抑制剂相关的免疫性血小板减少症（ICI-ITP）此前仅在个案报告和小型病例系列中有所描述，但其发病率、危险因素、临床特征、治疗及预后等方面的综合数据仍然不足。我们回顾性分析了2016年至2023年间在美国7个主要癌症中心下属29家医院接受ICI治疗的全部成年患者病历，以识别ICI-ITP病例。采用多变量逻辑回归模型确定危险因素，并利用Cox模型评估ICI-ITP及其严重程度与死亡率之间的关联。在86,467例患者中，共发现214例（0.25%）发生ICI-ITP。独立危险因素包括较低的基线血小板计数、联合ICI治疗、4期癌症以及伴随其他免疫相关不良事件。ICI-ITP通常在ICI起始治疗后中位8周（四分位距4–18周）发生，其血小板最低中位值为41×10⁹/L（四分位距17–64）。治疗方式包括糖皮质激素（n=106，49.5%）、免疫球蛋白（n=39，18.2%）及血小板生成素受体激动剂（n=29，13.6%）。共有161例患者（75.2%）实现恢复，中位恢复时间为2.3周（四分位距1.0–5.3）。在76例重新接受ICI治疗的患者中，有23例（30.3%）再次出现ICI-ITP。ICI-ITP及其严重程度与更高的全因死亡风险显著相关，严重ICI-ITP患者的风险较未发生ICI-ITP者增加近三倍（校正后的风险比2.96，95%置信区间2.14–4.08）。这些结果表明，ICI-ITP虽罕见但具有重要的临床意义，首次以大规模数据描绘了其危险因素与疾病过程，并强调了及时识别和处理的重要性。

### 第二部分 AI 大师评价

本研究通过大规模多中心回顾性分析，系统揭示了免疫检查点抑制剂相关免疫性血小板减少症的发生率、危险因素及临床转归。研究发现，尽管ICI-ITP罕见，但严重病例显著增加患者的死亡风险。所采用的统计模型科学严谨，结果为临床管理提供了重要依据。其创新价值在于首次基于全国多中心数据全面刻画该并发症的流行病学特征，但由于为回顾性设计，可能存在潜在的病例识别偏倚。

---

## 44. 从基因组学视角看多发性骨髓瘤的演化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359792)
**期刊：** Blood
**PMID：** 41359792
**DOI：** 10.1182/blood.2024026313

### 第一部分 原文与翻译

**英文原标题：** Evolution of Multiple Myeloma from a Genomic Perspective.

> **英文摘要：**
> In this review we explore the role of complex interactions between genomic evolution, environmental and genetic predispositions, and immune surveillance in disease progression from precursor conditions smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM). MM is well-described to be universally preceded by precursor states, often decades before it is even diagnosed. Genetic predisposition plays an important role in the initial transformation and is driven by both germline variants and MM-specific loci influencing risk. The reported disparities in occurrence of precursor conditions and MM among racial groups highlights the role of predisposition and the need for broader cohort studies. Early genomic events, such as translocations and hyperdiploidy, are essential in precursor initiation. However, additional factors are usually needed to transform the precursor stages into symptomatic disease, such as positive selection of subclonal populations. This process is impacted by aging, environmental factors such as exposures to Agent Orange and agrochemicals. Therefore, integrating genomic and transcriptomic data and combining them with immune profiling or other clinical features is essential for identifying patients with high risk of progressing into MM. Here, we highlight the complexity of myelomagenesis and underline the importance of state-of-the-art approaches for improved disease prediction.

> **中文摘要：**
> 在本综述中，我们探讨了基因组演化、环境和遗传易感性以及免疫监视之间复杂相互作用在疾病从前驱状态——惰性多发性骨髓瘤（SMM）和意义未明单克隆免疫球蛋白病（MGUS）——向多发性骨髓瘤（MM）进展中的作用。研究表明，几乎所有的MM都存在前驱阶段，且通常在确诊前已持续数十年。遗传易感性在最初转化过程中起到重要作用，这一过程由生殖系变异及影响风险的MM特异性位点共同驱动。不同种族群体间前驱状态及MM患病率的差异提示了遗传易感的作用，并显示出开展更大规模队列研究的必要性。早期基因组事件（如易位与高倍体）对于前驱状态的发生至关重要。然而，通常还需要其他因素才能使前驱阶段转变为有症状的疾病，例如亚克隆群体的正向选择。该过程受衰老及环境因素的影响，如接触橙剂和农业化学品。因此，整合基因组与转录组数据，并结合免疫谱分析或其他临床特征，对于识别具有高MM进展风险的患者至关重要。本文强调了骨髓瘤发生过程的复杂性，并突出了采用最先进的研究方法以改进疾病预测的重要性。

### 第二部分 AI 大师评价

该综述系统阐述了多发性骨髓瘤从前驱状态到症状性疾病的演化机制，聚焦于基因组学、免疫监控及环境因素的交互作用。作者总结了关键的早期基因组事件并强调遗传易感性在疾病启动中的决定性作用，同时指出环境暴露与衰老对疾病进展的促进影响。其创新性在于提出整合多组学与免疫特征的精准预测策略，旨在早期识别高风险患者。尽管综述内容全面，仍需更多前瞻性研究验证相关分子机制及预测模型的临床实用性。

---

## 45. 阿扎胞苷治疗MDS/AML患者可测残留病灶（MRD）：RELAZA2试验的最终长期结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359791)
**期刊：** Blood
**PMID：** 41359791
**DOI：** 10.1182/blood.2025030816

### 第一部分 原文与翻译

**英文原标题：** Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

> **英文摘要：**
> Measurable residual disease (MRD) can predict relapse in patients with advanced myelodysplastic neoplasms (MDS) or acute myeloid leukemia (AML). We report the long-term efficacy and safety of MRD-guided preemptive azacitidine treatment to prevent relapse in the phase 2 RELAZA2 trial. Patients with MDS or AML after either intensive chemotherapy only or consecutive allogeneic stem cell transplantation were prospectively screened for imminent relapse by molecular MRD assessment. Patients who became MRD positive (MRDpos) during screening received azacitidine for up to 2 years to prevent relapse. The primary endpoint was the proportion of patients alive and relapse-free six months after azacitidine start. Of 357 patients screened, 119 (33.3%) became MRDpos, of whom 95 (79.8%) were eligible for azacitidine treatment. The primary endpoint was met; 60 (63%) patients were relapse-free (95% confidence interval 54-71%, P<0.0001) six months after azacitidine initiation with no new safety signals. Of 60 patients achieving MRD response during the first six cycles of azacitidine, 31 (52%) maintained response without hematological relapse for ≥2 years following azacitidine initiation. The median treatment-free duration following azacitidine discontinuation was 20.8 months; the longest ongoing response was 104 months. After a median follow-up of 6.6 years, 15 initial responders (25%) remained alive and in remission. Among screened patients who remained continuously MRDneg, 60-month overall survival and relapse-free survival were 88% and 79%, respectively. Continuously MRDneg patients display a very favorable prognosis. A majority of MRDpos patients can be effectively treated with azacitidine with potential long-term remission even after termination of azacitidine. Clinicaltrials.gov: NCT01462578.

> **中文摘要：**
> 可测残留病灶（MRD）能够预测晚期骨髓增生异常性肿瘤（MDS）或急性髓系白血病（AML）患者的复发风险。我们报告了在Ⅱ期RELAZA2试验中，基于MRD指导的预防性阿扎胞苷治疗在防止复发方面的长期疗效与安全性。MDS或AML患者在接受单纯强化化疗或连续异基因造血干细胞移植后，通过分子MRD检测前瞻性筛查潜在复发风险。在筛查过程中出现MRD阳性（MRDpos）的患者接受为期最长2年的阿扎胞苷治疗以防止复发。主要终点为自阿扎胞苷治疗开始后6个月时仍存活且未复发的患者比例。在357例筛查患者中，119例（33.3%）出现MRD阳性，其中95例（79.8%）符合阿扎胞苷治疗条件。主要终点达成：在阿扎胞苷治疗6个月后，60例（63%）患者无复发（95%置信区间54–71%，P<0.0001），且未发现新的安全性信号。在阿扎胞苷前六个疗程中获得MRD缓解的60例患者中，有31例（52%）自阿扎胞苷治疗开始后≥2年内保持缓解且无血液学复发。停用阿扎胞苷后的中位无治疗持续时间为20.8个月；最长持续缓解时间为104个月。在中位随访6.6年时，15例最初应答者（25%）仍然存活且维持缓解。在持续MRD阴性的筛查患者中，60个月总体生存率和无复发生存率分别为88%和79%。持续MRD阴性的患者显示出极为良好的预后。多数MRD阳性患者可通过阿扎胞苷获得有效治疗，即使停药后亦可维持长期缓解。Clinicaltrials.gov编号：NCT01462578。

### 第二部分 AI 大师评价

该研究基于RELAZA2Ⅱ期试验，评估了MRD指导的预防性阿扎胞苷治疗在MDS/AML患者中防止复发的长期疗效与安全性。结果显示，阿扎胞苷可显著延长MRD阳性患者的无复发生存期，部分患者在停药后仍可保持长期缓解，提示其具有潜在的疾病控制与免疫重塑效应。持续MRD阴性患者的预后极为良好，支持MRD作为临床决策的重要生物标志。研究的创新之处在于验证了基于MRD监测的治疗策略的长期获益，但其样本量与非随机设计可能限制结论的普适性。

---

## 46. 加巴喷丁在胶质母细胞瘤治疗中的再利用：结合主动对照的真实世界数据分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359781)
**期刊：** Neuro-oncology
**PMID：** 41359781
**DOI：** 10.1093/neuonc/noaf280

### 第一部分 原文与翻译

**英文原标题：** Gabapentin repurposing for glioblastoma therapy: Real-world data analyses augmented by use of active comparators.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究旨在探讨加巴喷丁（Gabapentin）在胶质母细胞瘤治疗中的重新定位潜力，采用真实世界数据并结合主动对照分析，以增强研究的比较有效性和临床相关性。尽管文献尚无摘要，但从标题推断，其重点在于药物再利用策略与临床证据整合方法。研究的创新点可能在于结合实际临床数据和对照分析验证疗效，而局限性则可能包括真实世界研究中潜在的偏倚与混杂因素。

---

## 47. 对Avery医生来信的回复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359775)
**期刊：** Neuro-oncology
**PMID：** 41359775
**DOI：** 10.1093/neuonc/noaf273

### 第一部分 原文与翻译

**英文原标题：** Response to letter from Dr. Avery.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文属于作者针对Avery医生来信的学术回复，通常用于澄清观点、回应批评或补充先前研究的解释。由于未提供摘要和正文，无法获悉具体讨论内容，但此类文章在学术交流中具有维护科学透明度和促进学术对话的重要功能。文章本身的创新性较低，但体现了神经肿瘤学领域严谨的学术互动机制。

---

## 48. 我们共同的责任：应对神经肿瘤学研究诚信所面临的挑战

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359773)
**期刊：** Neuro-oncology
**PMID：** 41359773
**DOI：** 10.1093/neuonc/noaf278

### 第一部分 原文与翻译

**英文原标题：** Our collective responsibility to address challenges facing research integrity in Neuro-Oncology.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本篇发表在《Neuro-Oncology》的文章强调了学术界在维护神经肿瘤学研究诚信方面的共同责任。作者可能呼吁研究者、编辑、机构与资助方共同建立更严格的诚信标准与监督机制，以应对科研不端或数据不透明等挑战。尽管文章无摘要，但标题暗示其重在倡导文化与制度层面的变革，而非实验性研究。该文的重要性在于推动该领域的学术自省与系统改进。

---

## 49. 度伐利尤单抗单药及其与特瑞利单抗或贝伐珠单抗联合用于不可切除肝细胞癌的T细胞受体及免疫基因表达药效动力学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359405)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41359405
**DOI：** 10.1158/1078-0432.CCR-25-1592

### 第一部分 原文与翻译

**英文原标题：** T Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.

> **英文摘要：**
> PURPOSE: In the phase I/II Study 22 (NCT02519348) trial, objective response rates were 24.0% with STRIDE (Single Tremelimumab Regular Interval Durvalumab), 21.3% with durvalumab plus bevacizumab (D+B), and 11.5% with durvalumab (D) monotherapy in unresectable hepatocellular carcinoma (uHCC). Increased proliferating CD8+ T cells were associated with improved efficacy of STRIDE versus D monotherapy. Here, analyses of changes in T cell clonal expansion and gene expression signatures (GES) in peripheral blood were performed to explore the mechanisms of action associated with the anti-cancer activity of STRIDE and D+B versus D monotherapy.
> 
> PATIENTS AND METHODS: Participants with uHCC and no prior immune checkpoint inhibitor therapy were enrolled. DNA and RNA were isolated from peripheral blood collected at baseline and at the end of the first treatment cycle. Baseline values and changes from baseline in T cell clonality and GES were measured across treatment arms, and associations with radiographic response were assessed.
> 
> RESULTS: There were no significant differences in baseline richness or Simpson clonality of T cells across treatment arms. STRIDE, but not D+B, elicited an increase in the number of expanded T cell clones versus D monotherapy; the increase was associated with clinical response. Both STRIDE and D+B upregulated interferon-gamma response GES compared with D alone, but other immune-related changes differed, with STRIDE showing upregulation of CD4+ and T effector signatures, while D+B upregulated interferon-alpha response and both myeloid cell and endothelial GES.
> 
> CONCLUSIONS: These findings suggest that STRIDE and D+B have distinct, and potentially complementary, mechanisms of action in uHCC.

> **中文摘要：**
> 目的：在I/II期22号研究（NCT02519348）中，针对不可切除性肝细胞癌（uHCC），STRIDE方案（单次特瑞利单抗联合规则间隔度伐利尤单抗）的客观缓解率为24.0%，度伐利尤单抗加贝伐珠单抗（D+B）为21.3%，而度伐利尤单抗（D）单药治疗为11.5%。CD8+T细胞增殖的增加与STRIDE方案相较于D单药的疗效改善相关。本研究通过分析外周血T细胞克隆扩增及基因表达特征（GES）的变化，以探讨STRIDE与D+B相对于D单药的抗癌作用机制。
> 
> 患者与方法：纳入无既往免疫检查点抑制剂治疗史的uHCC患者。从基线及首个治疗周期结束时采集外周血，提取DNA与RNA。测定各治疗组T细胞克隆多样性及GES的基线值与基线变化，并评估其与影像学反应的相关性。
> 
> 结果：不同治疗组间基线时T细胞的丰富度或Simpson克隆多样性无显著差异。STRIDE方案而非D+B方案相较于D单药可诱导更多扩增的T细胞克隆，其增加与临床反应相关。与仅用D相比，STRIDE与D+B均上调干扰素-γ反应GES，但其他免疫相关变化有所不同：STRIDE上调CD4+及T效应细胞特征，而D+B上调干扰素-α反应以及髓系细胞和内皮细胞GES。
> 
> 结论：这些结果提示STRIDE与D+B在uHCC中具有不同且可能互补的作用机制。

### 第二部分 AI 大师评价

该研究旨在阐明度伐利尤单抗单药及其与特瑞利单抗或贝伐珠单抗联合在不可切除肝细胞癌中的免疫药效学差异。利用外周血T细胞克隆扩增及基因表达谱分析，比较不同治疗方案的免疫应答模式。结果显示STRIDE方案能诱导更多T细胞克隆扩增并激活T效应途径，而D+B更侧重于干扰素-α及髓系细胞相关通路。研究创新性地揭示了两种联合免疫策略的差异化免疫机制，为疗法优化提供了生物学依据，但样本与时间窗口的限制可能影响机制推断的全面性。

---

## 50. 接受PD-1/L1抗体和同时抗病毒预防治疗的肝细胞癌患者中HBV再激活的前瞻性观察研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359400)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41359400
**DOI：** 10.1158/1078-0432.CCR-25-2859

### 第一部分 原文与翻译

**英文原标题：** HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study.

> **英文摘要：**
> PURPOSE: Immune checkpoint inhibitors (ICIs)-related trials in hepatocellular carcinoma (HCC) have strict restrictions on HBV DNA load because of HBV reactivation. This study aimed to compare the HBV reactivation between HCC patients with low or high HBV DNA loads receiving ICIs and antiviral therapy.
> 
> PATIENTS AND METHODS: This prospective observational study (NCT04680598) recruited HBsAg-positive HCC patients who received concurrent antiviral therapy with initial ICI treatment. Participants were divided into HBV DNA-low (≤ 500 IU/ml) and HBV DNA-high (> 500 IU/ml) groups. The primary endpoint was the HBV reactivation rate.
> 
> RESULTS: Between December 25, 2020 and February 23, 2024, 356 and 659 participants were enrolled in the HBV DNA-low and HBV DNA-high groups. The HBV DNA-high group included significantly higher proportions of patients with HBeAg positivity (24.1% vs 7.0%, p < 0.001), ALBI grade 2-3 (49.9% vs. 33.7%, p < 0.001), and BCLC stage C (83.3% vs. 72.5%, p < 0.001). The HBV reactivation rate (4.5% vs. 6.1%, relative risk, 1.24; 95% CI: 0.81-1.89; p = 0.29), frequencies of HBV reactivation-associated hepatitis (1.7% vs. 2.3%, p = 0.53), and interruptions in ICI treatment (25.8% vs. 30.5%, p = 0.12) were comparable in the HBV DNA-low group and HBV DNA-high group.
> 
> CONCLUSIONS: There was no significantly difference in the risk of HBV reactivation between HCC patients with HBV DNA ≤ 500 IU/ml or HBV DNA > 500 IU/ml when treated with ICIs and concurrent antiviral prophylaxis.

> **中文摘要：**
> 研究目的：由于存在HBV再激活风险，肝细胞癌（HCC）患者接受免疫检查点抑制剂（ICI）治疗的相关临床试验对HBV DNA载量有严格限制。本研究旨在比较HBV DNA载量低或高的HCC患者在接受ICI及抗病毒治疗时HBV再激活的情况。
> 
> 患者与方法：本前瞻性观察研究（NCT04680598）纳入接受ICI初始治疗并同步接受抗病毒治疗的HBsAg阳性HCC患者。研究对象分为HBV DNA低载量组（≤500 IU/ml）和高载量组（>500 IU/ml）。主要终点为HBV再激活发生率。
> 
> 研究结果：2020年12月25日至2024年2月23日期间，分别有356名和659名患者纳入HBV DNA低载量组及高载量组。HBV DNA高载量组中HBeAg阳性（24.1% vs 7.0%，p < 0.001）、ALBI 2-3级（49.9% vs 33.7%，p < 0.001）及BCLC C期（83.3% vs 72.5%，p < 0.001）患者比例显著更高。HBV再激活率（4.5% vs 6.1%，相对风险1.24；95%CI: 0.81-1.89；p = 0.29）、HBV再激活相关性肝炎发生频率（1.7% vs 2.3%，p = 0.53）以及ICI治疗中断率（25.8% vs 30.5%，p = 0.12）在两组间差异均无统计学意义。
> 
> 结论：在接受ICI及同时抗病毒预防治疗的HCC患者中，HBV DNA ≤500 IU/ml与>500 IU/ml者的HBV再激活风险无显著差异。

### 第二部分 AI 大师评价

该研究以前瞻性观察设计探讨了肝细胞癌患者在接受PD-1/L1免疫治疗并同步抗病毒预防时，HBV DNA载量对再激活风险的影响。结果显示，无论初始HBV DNA载量高低，HBV再激活率和相关肝炎发生率均相似。该研究为免疫治疗合并HBV感染患者的管理提供了重要的真实世界数据支持。研究优点在于前瞻性设计与较大样本量，但受限于观察性研究性质及随访时间，仍需后续验证其长期安全性。

---

## 51. 为早期乳腺癌中辅助性 CDK4/6 抑制剂的应用辩护

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41202197)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41202197
**DOI：** 10.1200/JCO-25-01440

### 第一部分 原文与翻译

**英文原标题：** In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本篇文章似为一篇短评或观点性论文，旨在为早期乳腺癌中使用 CDK4/6 抑制剂的辅助治疗策略进行辩护或重新阐述其合理性。作者可能针对近期临床试验结果或指南更新所引发的争议提出建设性论点。尽管缺乏摘要限制了对具体论证与数据支撑的了解，但文章可能在临床决策和药物经济性评估等方面具有启发意义。整体上，内容更偏向学术争鸣与临床实践立场的探讨。

---

## 52. H-1B签证项目及其对医疗卫生领域的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41160009)
**期刊：** JAMA
**PMID：** 41160009
**DOI：** 10.1001/jama.2025.19626

### 第一部分 原文与翻译

**英文原标题：** H-1B Visa Program and Implications for Health Care.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要不可用。

### 第二部分 AI 大师评价

本研究可能探讨H-1B签证项目在医疗体系中的作用及其政策层面的影响。其核心议题包括外籍专业人员在医疗人力资源中的地位、签证制度对医疗服务可及性与质量的潜在影响，以及相关政策调整的挑战。尽管缺乏摘要，推测该文旨在为医疗劳动力政策与国际人才流动提供实证或政策分析视角。研究的创新性或许在于将移民政策与医疗可持续性结合讨论，但可能受限于数据覆盖面或政策时效性。

---

## 53. 勘误：基于瘦体重计算奥沙利铂剂量对Ⅲ期结肠癌辅助治疗中神经毒性的影响——LEANOX II期随机试验结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41150998)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41150998
**DOI：** 10.1200/JCO-25-02239

### 第一部分 原文与翻译

**英文原标题：** Erratum: Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可供参考。

### 第二部分 AI 大师评价

本文为关于LEANOX II期随机试验的勘误说明，该研究探讨了在Ⅲ期结肠癌辅助化疗中，基于瘦体重计算的奥沙利铂剂量对神经毒性发生的影响。此项研究旨在通过个体化剂量策略优化化疗耐受性与疗效平衡。尽管当前文本仅为勘误，无新增数据，但提示研究对改善结肠癌辅助治疗毒性管理具有重要临床意义。

---

## 54. POLARIX研究中Pola-R-CHP与R-CHOP治疗弥漫性大B细胞淋巴瘤患者的五年随访结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40991874)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 40991874
**DOI：** 10.1200/JCO-25-00925

### 第一部分 原文与翻译

**英文原标题：** Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

> **英文摘要：**
> In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL; median follow-up: 28 months). In this 5-year update, sustained PFS benefits favoring Pola-R-CHP were observed. In the global intention-to-treat population (N = 879; median follow-up: 64.1 months), Pola-R-CHP demonstrated a significant PFS benefit over R-CHOP (hazard ratio [HR], 0.77 [95% CI, 0.62 to 0.97]), with 5-year PFS rates of 64.9% (95% CI, 59.8 to 70.0) and 59.1% (95% CI, 53.9 to 64.3), respectively. Although not statistically significant, overall survival analysis showed a HR of 0.85 (95% CI, 0.63 to 1.15) at the 5-year data cut compared with 0.94 (95% CI, 0.67 to 1.33) at the 2-year data cut. In the expanded population, 46 and 62 patients had lymphoma-related deaths in the Pola-R-CHP and R-CHOP arms, respectively. Exploratory analyses showed favorable 5-year survival rates with Pola-R-CHP in high-risk subgroups, including activated B-cell DLBCL and International Prognostic Index score 3-5. Long-term tolerability was similar between treatment arms. Findings confirm Pola-R-CHP represents a standard of care for frontline treatment of DLBCL.

> **中文摘要：**
> 在POLARIX研究（ClinicalTrials.gov登记号：NCT03274492）中，波利妥珠单抗维多汀联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松（Pola-R-CHP），与利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）相比，在既往未治疗的中高危弥漫性大B细胞淋巴瘤（DLBCL）患者中显示出显著的无进展生存期（PFS）获益（中位随访28个月）。在本次5年随访更新中，观察到有利于Pola-R-CHP方案的持续PFS获益。在全球意向性治疗人群中（N = 879；中位随访64.1个月），Pola-R-CHP较R-CHOP显示出显著的PFS优势（风险比[HR]为0.77［95%置信区间，0.62至0.97］），其5年PFS率分别为64.9%（95% CI，59.8至70.0）与59.1%（95% CI，53.9至64.3）。尽管总体生存（OS）差异未达到统计学显著性，但在5年数据截点时，其HR为0.85（95% CI，0.63至1.15），较2年数据截点时的HR 0.94（95% CI，0.67至1.33）有所改善。在扩展人群中，Pola-R-CHP组与R-CHOP组分别有46例和62例因淋巴瘤相关死亡。探索性分析显示，在高危亚组（包括活化B细胞型DLBCL和国际预后指数评分3–5者）中，Pola-R-CHP方案获得更有利的5年生存率。两组间长期耐受性相似。本研究结果确认，Pola-R-CHP已成为DLBCL一线治疗的新护理标准。

### 第二部分 AI 大师评价

本研究旨在评估Pola-R-CHP方案在弥漫性大B细胞淋巴瘤患者中的长期疗效与安全性。结果显示，经过约五年随访，Pola-R-CHP在无进展生存方面持续优于传统的R-CHOP方案，尤其在高危亚组中表现更为突出。虽然总体生存差异未达到统计学显著性，但趋势仍支持Pola-R-CHP的长期优势。研究设计严谨、数据充分，进一步巩固了Pola-R-CHP作为DLBCL标准一线治疗方案的地位，但仍需更长期随访以观察总体生存获益。

---

速递结束，祝您工作愉快！